Journal Article
. 2015 Apr; 372(21):2018-28.
doi: 10.1056/NEJMoa1501824.

Pembrolizumab for the treatment of non-small-cell lung cancer

Edward B Garon 1 Naiyer A Rizvi  Rina Hui  Natasha Leighl  Ani S Balmanoukian  Joseph Paul Eder  Amita Patnaik  Charu Aggarwal  Matthew Gubens  Leora Horn  Enric Carcereny  Myung-Ju Ahn  Enriqueta Felip  Jong-Seok Lee  Matthew D Hellmann  Omid Hamid  Jonathan W Goldman  Jean-Charles Soria  Marisa Dolled-Filhart  Ruth Z Rutledge  Jin Zhang  Jared K Lunceford  Reshma Rangwala  Gregory M Lubiniecki  Charlotte Roach  Kenneth Emancipator  Leena Gandhi  KEYNOTE-001 Investigators  
  • PMID: 25891174
  •     2361 citations


Background: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit.

Methods: We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review.

Results: Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached.

Conclusions: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 number, NCT01295827.).

Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
Lisa Hutchinson.
Nat Rev Clin Oncol, 2015 May 13; 12(7). PMID: 25963092
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Luisa Carbognin, Sara Pilotto, +11 authors, Giampaolo Tortora.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086854    Free PMC article.
Highly Cited.
Challenges and future perspectives of T cell immunotherapy in cancer.
Maria Teresa P de Aquino, Anshu Malhotra, Manoj K Mishra, Anil Shanker.
Immunol Lett, 2015 Jun 23; 166(2). PMID: 26096822    Free PMC article.
JITC launches a new section: commentary and editorials.
Christian M Capitini, Pedro Romero.
J Immunother Cancer, 2015 Jun 26; 3. PMID: 26110058    Free PMC article.
Assays for predicting and monitoring responses to lung cancer immunotherapy.
Cristina Teixidó, Niki Karachaliou, +2 authors, Rafael Rosell.
Cancer Biol Med, 2015 Jul 16; 12(2). PMID: 26175924    Free PMC article.
CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Lena M Kranz, Matthias Birtel, +8 authors, Mustafa Diken.
Hum Vaccin Immunother, 2015 Jul 18; 12(1). PMID: 26186022    Free PMC article.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
Update in Lung Cancer 2014.
Avrum Spira, Balazs Halmos, Charles A Powell.
Am J Respir Crit Care Med, 2015 Aug 01; 192(3). PMID: 26230235    Free PMC article.
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu.
J Hematol Oncol, 2015 Aug 02; 8. PMID: 26231785    Free PMC article.
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
Jiabei He, Ying Hu, Mingming Hu, Baolan Li.
Sci Rep, 2015 Aug 19; 5. PMID: 26279307    Free PMC article.
Highly Cited. Review.
Leila Khoja, Marcus O Butler, +2 authors, Anthony M Joshua.
J Immunother Cancer, 2015 Aug 20; 3. PMID: 26288737    Free PMC article.
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
Xinbing Sui, Junhong Ma, +5 authors, Li Zhang.
Oncotarget, 2015 Aug 26; 6(23). PMID: 26305724    Free PMC article.
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Lars Henning Schmidt, Andreas Kümmel, +13 authors, Wolfgang Hartmann.
PLoS One, 2015 Aug 28; 10(8). PMID: 26313362    Free PMC article.
Highly Cited.
[Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
S Laban, J Doescher, +4 authors, T K Hoffmann.
HNO, 2015 Sep 01; 63(9). PMID: 26319429
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Gregory A Masters, Sarah Temin, +12 authors, American Society of Clinical Oncology Clinical Practice.
J Clin Oncol, 2015 Sep 02; 33(30). PMID: 26324367    Free PMC article.
Highly Cited.
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
Lieping Chen, Xue Han.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325035    Free PMC article.
Highly Cited. Review.
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu.
J Hematol Oncol, 2015 Sep 05; 8. PMID: 26337639    Free PMC article.
Management of Dermatologic Complications of Lung Cancer Therapies.
Silvina B Pugliese, Joel W Neal, Bernice Y Kwong.
Curr Treat Options Oncol, 2015 Sep 05; 16(10). PMID: 26338208
Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.
Alice Pasini, Angelo Delmonte, +2 authors, Emanuele Giordano.
Drugs, 2015 Sep 09; 75(15). PMID: 26347133
Novel Immune Check-Point Regulators in Tolerance Maintenance.
Yanxia Guo, Adele Y Wang.
Front Immunol, 2015 Sep 09; 6. PMID: 26347744    Free PMC article.
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.
Yuchen Fan, James J Moon.
Vaccines (Basel), 2015 Sep 10; 3(3). PMID: 26350600    Free PMC article.
Highly Cited. Review.
The Evolution of Therapies in Non-Small Cell Lung Cancer.
Vishal Boolell, Muhammad Alamgeer, David N Watkins, Vinod Ganju.
Cancers (Basel), 2015 Sep 16; 7(3). PMID: 26371045    Free PMC article.
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J Naidoo, D B Page, +5 authors, J D Wolchok.
Ann Oncol, 2015 Sep 16; 26(12). PMID: 26371282    Free PMC article.
Highly Cited. Review.
Targeting C-Type Lectin Receptors for Cancer Immunity.
Huimin Yan, Tomomori Kamiya, Papawee Suabjakyong, Noriko M Tsuji.
Front Immunol, 2015 Sep 18; 6. PMID: 26379663    Free PMC article.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Ahmad A Tarhini, Haris Zahoor, +6 authors, John M Kirkwood.
J Transl Med, 2015 Oct 01; 13. PMID: 26419843    Free PMC article.
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.
Claudia Voena, Matteo Menotti, +19 authors, Roberto Chiarle.
Cancer Immunol Res, 2015 Oct 01; 3(12). PMID: 26419961    Free PMC article.
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Su-Jin Shin, Yoon Kyung Jeon, +4 authors, Heounjeong Go.
Oncologist, 2015 Oct 02; 20(11). PMID: 26424759    Free PMC article.
AACR Cancer Progress Report 2015.
José Baselga, Nina Bhardwaj, +11 authors, Eva Szabo.
Clin Cancer Res, 2015 Oct 03; 21(19 Suppl). PMID: 26429991    Free PMC article.
Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Manish R Patel, Blake A Jacobson, +12 authors, Robert A Kratzke.
Oncotarget, 2015 Oct 03; 6(32). PMID: 26431376    Free PMC article.
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis.
Baohua Huang, Lei Chen, +4 authors, Xia Zhang.
Onco Targets Ther, 2015 Oct 10; 8. PMID: 26451118    Free PMC article.
Endocrine resistance in breast cancer--An overview and update.
Robert Clarke, John J Tyson, J Michael Dixon.
Mol Cell Endocrinol, 2015 Oct 13; 418 Pt 3. PMID: 26455641    Free PMC article.
Highly Cited. Review.
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.
Terry R Medler, Tiziana Cotechini, Lisa M Coussens.
Trends Cancer, 2015 Oct 13; 1(1). PMID: 26457331    Free PMC article.
Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.
Benjamin Goeppert, Lena Frauenschuh, +9 authors, Wilko Weichert.
Br J Cancer, 2015 Oct 16; 113(9). PMID: 26461054    Free PMC article.
Immunological landscape and immunotherapy of hepatocellular carcinoma.
Jesús Prieto, Ignacio Melero, Bruno Sangro.
Nat Rev Gastroenterol Hepatol, 2015 Oct 21; 12(12). PMID: 26484443
Highly Cited. Review.
Advances in immunotherapy for treatment of lung cancer.
Jean G Bustamante Alvarez, María González-Cao, +4 authors, Rafael Rosell.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487966    Free PMC article.
Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy.
Cristina Teixidó, Niki Karachaliou, +2 authors, Rafael Rosell.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487971    Free PMC article.
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Matthias Preusser, Anna S Berghoff, Wolfgang Wick, Michael Weller.
Clin Neuropathol, 2015 Oct 27; 34(6). PMID: 26501438    Free PMC article.
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.
Yiyi Yan, Axel Grothey.
Onco Targets Ther, 2015 Oct 29; 8. PMID: 26508880    Free PMC article.
Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
Hae Su Kim, Ji Yun Lee, +10 authors, Myung-Ju Ahn.
Cancer Res Treat, 2015 Oct 30; 48(2). PMID: 26511814    Free PMC article.
Nivolumab: a review in advanced squamous non-small cell lung cancer.
Gillian M Keating.
Drugs, 2015 Oct 31; 75(16). PMID: 26514815
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
Marissa Mayor, Neng Yang, +2 authors, Prasad S Adusumilli.
Eur J Cardiothorac Surg, 2015 Oct 31; 49(5). PMID: 26516195    Free PMC article.
Immunomodulation: checkpoint blockade etc.
William T Curry, Michael Lim.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516223    Free PMC article.
Novel immunotherapies in lymphoid malignancies.
Connie Lee Batlevi, Eri Matsuki, Renier J Brentjens, Anas Younes.
Nat Rev Clin Oncol, 2015 Nov 04; 13(1). PMID: 26525683    Free PMC article.
Highly Cited. Review.
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
Kathleen M Mahoney, Heather Sun, +8 authors, Gordon J Freeman.
Cancer Immunol Res, 2015 Nov 08; 3(12). PMID: 26546452    Free PMC article.
Highly Cited.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis.
Lucheng Zhu, Saisai Jing, +3 authors, Shirong Zhang.
Pathol Oncol Res, 2015 Nov 11; 22(2). PMID: 26552662
The changing landscape of phase I trials in oncology.
Kit Man Wong, Anna Capasso, S Gail Eckhardt.
Nat Rev Clin Oncol, 2015 Nov 11; 13(2). PMID: 26552953
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Joseph McLaughlin, Gang Han, +7 authors, David L Rimm.
JAMA Oncol, 2015 Nov 13; 2(1). PMID: 26562159    Free PMC article.
Highly Cited.
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.
Sarah L Scarpace.
Drugs Context, 2015 Nov 18; 4. PMID: 26576187    Free PMC article.
[Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer].
Zhiyu Huang, Hui Li, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2015 Nov 20; 18(11). PMID: 26582228    Free PMC article.
[Molecular tumour therapy].
C Michel, A Neubauer, A Burchert.
Internist (Berl), 2015 Nov 21; 56(12). PMID: 26585240
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Thu Oanh Dang, Adebayo Ogunniyi, Meagan S Barbee, Alexander Drilon.
Expert Rev Anticancer Ther, 2015 Nov 22; 16(1). PMID: 26588948    Free PMC article.
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
Shundong Cang, Chaitanya Iragavarapu, +2 authors, Delong Liu.
J Hematol Oncol, 2015 Nov 22; 8. PMID: 26589495    Free PMC article.
Highly Cited. Review.
Landscape of Tumor Antigens in T Cell Immunotherapy.
Sadia Ilyas, James C Yang.
J Immunol, 2015 Nov 22; 195(11). PMID: 26589749    Free PMC article.
Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Zoran Gatalica, Semir Vranic, +10 authors, Barbara Pockaj.
Oncotarget, 2015 Dec 02; 7(2). PMID: 26625196    Free PMC article.
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Silvia Darb-Esfahani, Catarina Alisa Kunze, +9 authors, Korinna Jöhrens.
Oncotarget, 2015 Dec 02; 7(2). PMID: 26625204    Free PMC article.
Highly Cited.
New strategies in immunotherapy for non-small cell lung cancer.
Daniel R Carrizosa, Kathryn A Gold.
Transl Lung Cancer Res, 2015 Dec 03; 4(5). PMID: 26629424    Free PMC article.
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Jeryl Villadolid, Asim Amin.
Transl Lung Cancer Res, 2015 Dec 03; 4(5). PMID: 26629425    Free PMC article.
Highly Cited. Review.
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.
Michael Hebeisen, Mathilde Allard, +3 authors, Nathalie Rufer.
Front Immunol, 2015 Dec 05; 6. PMID: 26635796    Free PMC article.
The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Mehrdad Talebian Yazdi, Sander van Riet, +5 authors, Sjoerd H van der Burg.
Oncotarget, 2015 Dec 15; 7(3). PMID: 26658106    Free PMC article.
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.
Aaron S Mansfield, Stephen J Murphy, +4 authors, Marie Christine Aubry.
Clin Cancer Res, 2015 Dec 17; 22(9). PMID: 26667490    Free PMC article.
Immunotherapy in Tumors.
Sebastian Kobold, Peter Duewell, +3 authors, Stefan Endres.
Dtsch Arztebl Int, 2015 Dec 17; 112(48). PMID: 26667979    Free PMC article.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Noura Choudhury, Yusuke Nakamura.
Cancer Sci, 2015 Dec 19; 107(2). PMID: 26678880    Free PMC article.
Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Young Wha Koh, Yoon Kyung Jeon, +2 authors, Jooryung Huh.
Tumour Biol, 2015 Dec 19; 37(6). PMID: 26678894
Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.
Egbert F Smit, Paul Baas.
Nat Rev Clin Oncol, 2016 Jan 01; 13(2). PMID: 26718109
Current progress in immunotherapy for pancreatic cancer.
Kelly Foley, Victoria Kim, Elizabeth Jaffee, Lei Zheng.
Cancer Lett, 2016 Jan 03; 381(1). PMID: 26723878    Free PMC article.
Highly Cited. Review.
Immune Checkpoint Blockade in Hepatocellular Carcinoma.
M Kudo.
Liver Cancer, 2016 Jan 07; 4(4). PMID: 26732472    Free PMC article.
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells.
Zhenzhen Hui, Xinwei Zhang, +2 authors, Xiubao Ren.
Front Immunol, 2016 Jan 07; 6. PMID: 26734004    Free PMC article.
Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Ashish Saxena, Bryan J Schneider, +3 authors, Ronald J Scheff.
Med Oncol, 2016 Jan 11; 33(2). PMID: 26749586    Free PMC article.
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio.
Ther Adv Med Oncol, 2016 Jan 12; 8(1). PMID: 26753003    Free PMC article.
Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.
Adarsh Vennepureddy, Nishitha Thumallapally, +2 authors, Terenig Terjanian.
J Clin Med Res, 2016 Jan 15; 8(2). PMID: 26767073    Free PMC article.
Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
Nita Ahuja, Anup R Sharma, Stephen B Baylin.
Annu Rev Med, 2016 Jan 16; 67. PMID: 26768237    Free PMC article.
Highly Cited. Review.
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Glenwood D Goss, Johanna N Spaans.
Oncologist, 2016 Jan 16; 21(2). PMID: 26768483    Free PMC article.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Immunotherapy for lung cancer.
María González-Cao.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798576    Free PMC article.
Lung cancer in HIV-infected patients in the combination antiretroviral treatment era.
José Moltó, Teresa Moran, Guillem Sirera, Bonaventura Clotet.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798577    Free PMC article.
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
Sara Pilotto, Luisa Carbognin, +6 authors, Emilio Bria.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798579    Free PMC article.
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.
Sara Pilotto, Miguel Angel Molina-Vila, +6 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798581    Free PMC article.
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.
Mariacarmela Santarpia, María González-Cao, +3 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798582    Free PMC article.
Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.
Nitin Chakravarti, Victor G Prieto.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798583    Free PMC article.
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
Santiago Viteri, María González-Cao, +2 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798585    Free PMC article.
Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?
Jeffrey M Clarke, Xiaofei Wang, Neal E Ready.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798592    Free PMC article.
Shedding light on the molecular determinants of response to anti-PD-1 therapy.
Ross A Soo.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798594    Free PMC article.
[China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)].
Yuankai Shi, Yan Sun, +46 authors, Yu Huang.
Zhongguo Fei Ai Za Zhi, 2016 Jan 26; 19(1). PMID: 26805732    Free PMC article.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, +18 authors, Justin M Balko.
Nat Commun, 2016 Jan 30; 7. PMID: 26822383    Free PMC article.
Highly Cited.
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
Patrick J Medina, Val R Adams.
Pharmacotherapy, 2016 Jan 30; 36(3). PMID: 26822752    Free PMC article.
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Shohei Koyama, Esra A Akbay, +30 authors, Kwok-Kin Wong.
Cancer Res, 2016 Feb 03; 76(5). PMID: 26833127    Free PMC article.
Highly Cited.
The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8+ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits.
Ruchi Srivastava, Xavier Dervillez, +11 authors, Lbachir BenMohamed.
J Virol, 2016 Feb 05; 90(8). PMID: 26842468    Free PMC article.
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Lee A Wheeler, Andrea G Manzanera, +14 authors, E Antonio Chiocca.
Neuro Oncol, 2016 Feb 05; 18(8). PMID: 26843484    Free PMC article.
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Don S Dizon, Lada Krilov, +17 authors, Gregory Masters.
J Clin Oncol, 2016 Feb 06; 34(9). PMID: 26846975    Free PMC article.
Highly Cited.
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
Yanyan Lou, Lixia Diao, +12 authors, Don L Gibbons.
Clin Cancer Res, 2016 Feb 07; 22(14). PMID: 26851185    Free PMC article.
Highly Cited.
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan.
Semin Immunol, 2016 Feb 11; 28(1). PMID: 26861544    Free PMC article.
Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches.
Paul L Swiecicki, Kelly M Malloy, Francis P Worden.
World J Clin Oncol, 2016 Feb 11; 7(1). PMID: 26862488    Free PMC article.
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Mizuki Nishino, Emily S Chambers, +7 authors, Mark M Awad.
Cancer Immunol Res, 2016 Feb 13; 4(4). PMID: 26865455    Free PMC article.
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Jeffrey Weber, Geoffrey Gibney, +11 authors, Yian Ann Chen.
Cancer Immunol Res, 2016 Feb 14; 4(4). PMID: 26873574    Free PMC article.
Highly Cited.
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Maria Alsina, Markus Moehler, +2 authors, Josep Tabernero.
Target Oncol, 2016 Feb 18; 11(4). PMID: 26880697
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, +23 authors, Peter S Hammerman.
Nat Commun, 2016 Feb 18; 7. PMID: 26883990    Free PMC article.
Highly Cited.
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy.
Wang Jing, Miaomiao Li, +4 authors, Hui Zhu.
Onco Targets Ther, 2016 Feb 19; 9. PMID: 26889087    Free PMC article.
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Chan-Young Ock, Sehui Kim, +12 authors, Dae Seog Heo.
Oncotarget, 2016 Feb 20; 7(13). PMID: 26893364    Free PMC article.
Highly Cited.
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Marius Ilie, Véronique Hofman, +2 authors, Paul Hofman.
Virchows Arch, 2016 Feb 26; 468(5). PMID: 26915032
Highly Cited. Review.
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
Francesco Passiglia, Giuseppe Bronte, +8 authors, Antonio Russo.
Oncotarget, 2016 Feb 27; 7(15). PMID: 26918451    Free PMC article.
Highly Cited.
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Claire F Friedman, Michael A Postow.
Curr Oncol Rep, 2016 Feb 29; 18(4). PMID: 26922327    Free PMC article.
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Jeffrey P Ward, Matthew M Gubin, Robert D Schreiber.
Adv Immunol, 2016 Mar 01; 130. PMID: 26922999    Free PMC article.
Highly Cited. Review.
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.
K M Morrissey, T M Yuraszeck, +2 authors, S Kasichayanula.
Clin Transl Sci, 2016 Mar 01; 9(2). PMID: 26924066    Free PMC article.
Highly Cited. Review.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Weiping Zou, Jedd D Wolchok, Lieping Chen.
Sci Transl Med, 2016 Mar 05; 8(328). PMID: 26936508    Free PMC article.
Highly Cited. Review.
Doubling the blockade for melanoma immunotherapy.
Lorenzo Galluzzi, Alexander Eggermont, Guido Kroemer.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942094    Free PMC article.
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Omar Abdel-Rahman, Mona Fouad.
Ther Adv Respir Dis, 2016 Mar 06; 10(3). PMID: 26944362    Free PMC article.
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.
Steffen Filskov Sorensen, Wei Zhou, +7 authors, Henrik Hager.
Transl Oncol, 2016 Mar 08; 9(1). PMID: 26947883    Free PMC article.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
Cellular and molecular biology of small cell lung cancer: an overview.
Niki Karachaliou, Sara Pilotto, +3 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Mar 10; 5(1). PMID: 26958489    Free PMC article.
Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
Abigail T Berman, Charles B Simone.
Transl Lung Cancer Res, 2016 Mar 10; 5(1). PMID: 26958509    Free PMC article.
The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
Thomas E Stinchcombe.
Curr Treat Options Oncol, 2016 Mar 11; 17(4). PMID: 26961971
Vaccines for established cancer: overcoming the challenges posed by immune evasion.
Sjoerd H van der Burg, Ramon Arens, +2 authors, Cornelis J M Melief.
Nat Rev Cancer, 2016 Mar 12; 16(4). PMID: 26965076
Highly Cited. Review.
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.
Robert Pirker, Martin Filipits.
Cancer Metastasis Rev, 2016 Mar 14; 35(1). PMID: 26970967    Free PMC article.
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Danny N Khalil, Eric L Smith, Renier J Brentjens, Jedd D Wolchok.
Nat Rev Clin Oncol, 2016 Mar 16; 13(5). PMID: 26977780    Free PMC article.
Highly Cited. Review.
Recognizing that the microbiome is part of the human immune system will advance treatment of both cancer and infections.
Richard L Gallo, Thomas Hultsch, Lauge Farnaes.
J Am Acad Dermatol, 2016 Mar 17; 74(4). PMID: 26979362    Free PMC article.
MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade.
Duane A Mitchell.
Neuro Oncol, 2016 Mar 17; 18(5). PMID: 26980424    Free PMC article.
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Dickran Kazandjian, Daniel L Suzman, +5 authors, Richard Pazdur.
Oncologist, 2016 Mar 18; 21(5). PMID: 26984449    Free PMC article.
Highly Cited.
Combining Epigenetic and Immunotherapy to Combat Cancer.
Katherine B Chiappinelli, Cynthia A Zahnow, Nita Ahuja, Stephen B Baylin.
Cancer Res, 2016 Mar 19; 76(7). PMID: 26988985    Free PMC article.
Highly Cited. Review.
Multispectral Imaging of T and B Cells in Murine Spleen and Tumor.
Zipei Feng, Shawn M Jensen, +4 authors, Bernard A Fox.
J Immunol, 2016 Mar 20; 196(9). PMID: 26994219    Free PMC article.
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
Toshio Shimizu, Takashi Seto, +9 authors, Kazuhiko Nakagawa.
Invest New Drugs, 2016 Mar 24; 34(3). PMID: 27000274    Free PMC article.
Systemic Immunotherapy for the Treatment of Brain Metastases.
Justine V Cohen, Harriet M Kluger.
Front Oncol, 2016 Mar 26; 6. PMID: 27014624    Free PMC article.
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
Joyce Liu, Shannon N Westin.
Gynecol Oncol, 2016 Mar 27; 141(1). PMID: 27016231    Free PMC article.
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Joohee Sul, Gideon M Blumenthal, +3 authors, Richard Pazdur.
Oncologist, 2016 Mar 31; 21(5). PMID: 27026676    Free PMC article.
Highly Cited.
Into the Clinic With Nivolumab and Pembrolizumab.
Catherine A Shu, Naiyer A Rizvi.
Oncologist, 2016 Mar 31; 21(5). PMID: 27026678    Free PMC article.
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Laura Graham, Michael T Schweizer.
Med Oncol, 2016 Apr 05; 33(5). PMID: 27042852
The Face of the Next Generation in China.
Chen Wang, Jinghong Li, Sinan Wu, Atul Malhotra.
Am J Respir Crit Care Med, 2016 Apr 05; 193(10). PMID: 27043074    Free PMC article.
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
V R Belum, B Benhuri, +8 authors, M E Lacouture.
Eur J Cancer, 2016 Apr 05; 60. PMID: 27043866    Free PMC article.
Highly Cited. Systematic Review.
Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Yusuke Inoue, Katsuhiro Yoshimura, +12 authors, Haruhiko Sugimura.
Oncotarget, 2016 Apr 07; 7(22). PMID: 27050074    Free PMC article.
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
A Drilon, I Bergagnini, +13 authors, M G Kris.
Ann Oncol, 2016 Apr 09; 27(7). PMID: 27056998    Free PMC article.
PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.
Shijie Yang, Qiuyang Zhang, +2 authors, Zongbing You.
Am J Clin Exp Urol, 2016 Apr 14; 4(1). PMID: 27069956    Free PMC article.
Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
Ila Datar, Kurt A Schalper.
Clin Cancer Res, 2016 Apr 15; 22(14). PMID: 27076625    Free PMC article.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.
Nam Bui, Brian Woodward, Anna Johnson, Hatim Husain.
Curr Treat Options Oncol, 2016 Apr 18; 17(5). PMID: 27085533
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Paul T Nghiem, Shailender Bhatia, +28 authors, Martin A Cheever.
N Engl J Med, 2016 Apr 20; 374(26). PMID: 27093365    Free PMC article.
Highly Cited.
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
Malaka Ameratunga, Khashayar Asadi, +6 authors, Thomas John.
PLoS One, 2016 Apr 23; 11(4). PMID: 27104612    Free PMC article.
Immune Checkpoint Therapies in Prostate Cancer.
Sangeeta Goswami, Ana Aparicio, Sumit K Subudhi.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111907    Free PMC article.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
M Chatterjee, D C Turner, +20 authors, Ø Fløtten.
Ann Oncol, 2016 Apr 28; 27(7). PMID: 27117531    Free PMC article.
PD-L1 Expression in Lung Cancer.
Hui Yu, Theresa A Boyle, +2 authors, Fred R Hirsch.
J Thorac Oncol, 2016 Apr 28; 11(7). PMID: 27117833    Free PMC article.
Highly Cited. Review.
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Amos Kirilovsky, Florence Marliot, +3 authors, Franck Pagès.
Int Immunol, 2016 Apr 29; 28(8). PMID: 27121213    Free PMC article.
Highly Cited. Review.
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, +9 authors, Laurence Buisseret.
J Clin Oncol, 2016 May 04; 34(21). PMID: 27138582    Free PMC article.
Highly Cited.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, +14 authors, Caroline Robert.
Nat Rev Clin Oncol, 2016 May 05; 13(8). PMID: 27141885
Highly Cited. Review.
Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.
Megan L Ludwig, Andrew C Birkeland, +3 authors, J Chad Brenner.
Cancer Biol Med, 2016 May 05; 13(1). PMID: 27144065    Free PMC article.
Pembrolizumab in classical Hodgkin's lymphoma.
Joseph Maly, Lapo Alinari.
Eur J Haematol, 2016 May 06; 97(3). PMID: 27147112    Free PMC article.
The Utility of Exercise Testing in Patients with Lung Cancer.
Duc Ha, Peter J Mazzone, +2 authors, Mark Fuster.
J Thorac Oncol, 2016 May 10; 11(9). PMID: 27156441    Free PMC article.
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Janice M Mehnert, Anshuman Panda, +16 authors, Shridar Ganesan.
J Clin Invest, 2016 May 10; 126(6). PMID: 27159395    Free PMC article.
Highly Cited.
The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival.
Thomas K Kilvaer, Erna-Elise Paulsen, +6 authors, Tom Donnem.
Br J Cancer, 2016 May 12; 114(10). PMID: 27167450    Free PMC article.
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Shin Yup Lee, Deuk Kju Jung, +14 authors, Jae Yong Park.
Sci Rep, 2016 May 18; 6. PMID: 27181838    Free PMC article.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide, Alexander Martens, +24 authors, Jedd D Wolchok.
Clin Cancer Res, 2016 Nov 01; 22(22). PMID: 27185375    Free PMC article.
Highly Cited.
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.
Gillian M Keating.
Drugs, 2016 May 18; 76(9). PMID: 27189706
Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Hong Zheng, Xin Liu, +7 authors, Chandra P Belani.
Oncotarget, 2016 May 19; 7(35). PMID: 27191652    Free PMC article.
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Eri Matsuki, Anas Younes.
Curr Treat Options Oncol, 2016 May 20; 17(6). PMID: 27193488    Free PMC article.
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Keith T Schmidt, Cindy H Chau, Douglas K Price, William D Figg.
J Clin Pharmacol, 2016 May 21; 56(12). PMID: 27197880    Free PMC article.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Saad Z Usmani, Brendan M Weiss, +15 authors, Hareth Nahi.
Blood, 2016 May 25; 128(1). PMID: 27216216    Free PMC article.
Highly Cited.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Jakub Krejcik, Tineke Casneuf, +11 authors, A Kate Sasser.
Blood, 2016 May 26; 128(3). PMID: 27222480    Free PMC article.
Highly Cited.
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Justin F Gainor, Alice T Shaw, +18 authors, Mari Mino-Kenudson.
Clin Cancer Res, 2016 May 27; 22(18). PMID: 27225694    Free PMC article.
Highly Cited.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino, Gerardo Botti, +5 authors, Paolo A Ascierto.
Drugs, 2016 May 28; 76(9). PMID: 27229745
Highly Cited. Review.
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
Benjamin M Larimer, Eric Wehrenberg-Klee, Alexander Caraballo, Umar Mahmood.
J Nucl Med, 2016 May 28; 57(10). PMID: 27230929    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Checkpoint Inhibitors and Their Application in Breast Cancer.
Davide Bedognetti, Cristina Maccalli, +2 authors, Barbara Seliger.
Breast Care (Basel), 2016 May 31; 11(2). PMID: 27239172    Free PMC article.
Immunotherapy for head and neck cancer: latest developments and clinical potential.
Joshua M Bauml, Roger B Cohen, Charu Aggarwal.
Ther Adv Med Oncol, 2016 May 31; 8(3). PMID: 27239235    Free PMC article.
Nintedanib in NSCLC: evidence to date and place in therapy.
Giuseppe Bronte, Francesco Passiglia, +7 authors, Antonio Russo.
Ther Adv Med Oncol, 2016 May 31; 8(3). PMID: 27239237    Free PMC article.
Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.
Y Sunakawa, S Cao, +16 authors, H-J Lenz.
Pharmacogenomics J, 2016 Jun 01; 17(6). PMID: 27241062    Free PMC article.
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
Jae W Lee, Chad A Komar, +2 authors, Gregory L Beatty.
Curr Protoc Pharmacol, 2016 Jun 02; 73. PMID: 27248578    Free PMC article.
Metabolic regulation of immune responses: therapeutic opportunities.
Nadine Assmann, David K Finlay.
J Clin Invest, 2016 Jun 02; 126(6). PMID: 27249676    Free PMC article.
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.
Georgia J B McCaughan, Michael J Fulham, +5 authors, Vivek A Bhadri.
J Hematol Oncol, 2016 Jun 05; 9(1). PMID: 27259563    Free PMC article.
Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.
Guillaume Desoubeaux, Janice M Reichert, +11 authors, Nathalie Heuze-Vourc'h.
MAbs, 2016 Jun 09; 8(6). PMID: 27266390    Free PMC article.
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Sarah B Goldberg, Scott N Gettinger, +18 authors, Harriet M Kluger.
Lancet Oncol, 2016 Jun 09; 17(7). PMID: 27267608    Free PMC article.
Highly Cited.
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.
Naoka Murakami, Thiago J Borges, Michifumi Yamashita, Leonardo V Riella.
Clin Kidney J, 2016 Jun 09; 9(3). PMID: 27274826    Free PMC article.
Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.
R Bhome, H A Al Saihati, +5 authors, A H Mirnezami.
New Horiz Transl Med, 2016 Jun 09; 3(1). PMID: 27275004    Free PMC article.
What does the future hold for immunotherapy in cancer?
Jarushka Naidoo, Bob T Li, Katja Schindler, David B Page.
Ann Transl Med, 2016 Jun 09; 4(9). PMID: 27275490    Free PMC article.
TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?
Ramon Andrade de Mello.
Ann Transl Med, 2016 Jun 09; 4(9). PMID: 27275498    Free PMC article.
Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.
Edward B Garon, Phillip A Abarca, +6 authors, Robert M Elashoff.
Crit Rev Oncog, 2015 Jan 01; 20(5-6). PMID: 27279233    Free PMC article.
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, +13 authors, Bruce E Johnson.
Lancet Oncol, 2016 Jun 11; 17(7). PMID: 27283860    Free PMC article.
Highly Cited.
Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.
Samuel K Kim, Cheng-Chia Wu, David P Horowitz.
J Gastrointest Oncol, 2016 Jun 11; 7(3). PMID: 27284482    Free PMC article.
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.
Nicole L K Pershing, Chi-Fu Jeffrey Yang, MengMeng Xu, Christopher M Counter.
Oncotarget, 2016 Jun 11; 7(27). PMID: 27285753    Free PMC article.
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Woo Young Sun, Yu Kyung Lee, Ja Seung Koo.
J Transl Med, 2016 Jun 12; 14(1). PMID: 27286842    Free PMC article.
Immune Checkpoint Inhibitors in Older Adults.
Rawad Elias, Joshua Morales, Yasser Rehman, Humera Khurshid.
Curr Oncol Rep, 2016 Jun 12; 18(8). PMID: 27287329
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
Edurne Arriola, Matthew Wheater, +13 authors, Christian Ottensmeier.
J Thorac Oncol, 2016 Jun 15; 11(9). PMID: 27296105    Free PMC article.
Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
Yayi He, Christopher J Rivard, +5 authors, Fred R Hirsch.
Cancer Sci, 2016 Jun 15; 107(9). PMID: 27297395    Free PMC article.
Highly Cited. Review.
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
Elisa González-Rodríguez, Delvys Rodríguez-Abreu, Spanish Group for Cancer Immuno-Biotherapy (GETICA).
Oncologist, 2016 Jun 17; 21(7). PMID: 27306911    Free PMC article.
Highly Cited. Review.
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Laura C Cappelli, Anna Kristina Gutierrez, +10 authors, Clifton O Bingham.
Ann Rheum Dis, 2016 Jun 17; 76(1). PMID: 27307501    Free PMC article.
Highly Cited.
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.
Marie Kostine, Arjen Hg Cleven, +3 authors, Judith V M G Bovée.
Mod Pathol, 2016 Jun 18; 29(9). PMID: 27312065
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.
Yvonne Le Ang, Joline Sj Lim, Ross A Soo.
Onco Targets Ther, 2016 Jun 18; 9. PMID: 27313464    Free PMC article.
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Dionisia Quiroga, H Kim Lyerly, Michael A Morse.
Curr Treat Options Oncol, 2016 Jun 18; 17(8). PMID: 27315067
Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Ken Hatogai, Shigehisa Kitano, +8 authors, Atsushi Ochiai.
Oncotarget, 2016 Jun 21; 7(30). PMID: 27322149    Free PMC article.
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Dickran Kazandjian, Gideon M Blumenthal, +4 authors, Richard Pazdur.
Oncologist, 2016 Jun 23; 21(8). PMID: 27328934    Free PMC article.
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.
Mehmet Asim Bilen, Sumit K Subudhi, +3 authors, Padmanee Sharma.
J Immunother Cancer, 2016 Jun 23; 4. PMID: 27330809    Free PMC article.
Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.
Howard L Kaufman, Lisa H Butterfield, +9 authors, Francesco M Marincola.
J Immunother Cancer, 2016 Jun 23; 4. PMID: 27330810    Free PMC article.
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Charlotte Roach, Nancy Zhang, +7 authors, Karina Kulangara.
Appl Immunohistochem Mol Morphol, 2016 Jun 23; 24(6). PMID: 27333219    Free PMC article.
Highly Cited.
Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.
Ana I Robles, Curtis C Harris.
Lung Cancer, 2016 Jun 28; 107. PMID: 27344275    Free PMC article.
Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.
Murali Janakiram, Vipul Pareek, +2 authors, Xingxing Zang.
Immunotherapy, 2016 Jun 29; 8(7). PMID: 27349980    Free PMC article.
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, +8 authors, Craig H Moskowitz.
J Clin Oncol, 2016 Jun 30; 34(31). PMID: 27354476    Free PMC article.
Highly Cited.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Naiyer A Rizvi, Matthew D Hellmann, +13 authors, Scott Antonia.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354481    Free PMC article.
Highly Cited.
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Leora Horn, Martin Reck, David R Spigel.
Oncologist, 2016 Jun 30; 21(8). PMID: 27354668    Free PMC article.
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.
Emanuela Veras, Robert J Kurman, Tian-Li Wang, Ie-Ming Shih.
Int J Gynecol Pathol, 2016 Jul 01; 36(2). PMID: 27362903    Free PMC article.
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
Seth P Lerner, Dean F Bajorin, +33 authors, Diane Zipursky Quale.
Bladder Cancer, 2016 Jul 05; 2(2). PMID: 27376138    Free PMC article.
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.
Deborah T Blumenthal, Michal Yalon, +6 authors, Felix Bokstein.
J Neurooncol, 2016 Jul 06; 129(3). PMID: 27377654
Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Natalie Vandeven, Paul Nghiem.
Immunotherapy, 2016 Jul 07; 8(8). PMID: 27381685    Free PMC article.
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.
Jun Wang, Baocheng Wang, Huili Chu, Yunfeng Yao.
Onco Targets Ther, 2016 Jul 07; 9. PMID: 27382309    Free PMC article.
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.
Giuseppe Santabarbara, Paolo Maione, +2 authors, Cesare Gridelli.
Ann Transl Med, 2016 Jul 08; 4(11). PMID: 27386489    Free PMC article.
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Andreas H Scheel, Manfred Dietel, +12 authors, Reinhard Buettner.
Mod Pathol, 2016 Jul 09; 29(10). PMID: 27389313
Highly Cited.
Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age.
Zhonglin Hao, Paul Biddinger, Carsten Schroeder, Khurram Tariq.
BMJ Case Rep, 2016 Jul 09; 2016. PMID: 27389724    Free PMC article.
Pembrolizumab (Keytruda).
Gerry Kwok, Thomas C C Yau, +2 authors, Yok-Lam Kwong.
Hum Vaccin Immunother, 2016 Jul 12; 12(11). PMID: 27398650    Free PMC article.
Clinician Perspectives on Current Issues in Lung Cancer Drug Development.
Saiama N Waqar, Philip D Bonomi, +17 authors, Gideon M Blumenthal.
J Thorac Oncol, 2016 Jul 13; 11(9). PMID: 27401214    Free PMC article.
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Veronica J Shi, Nemanja Rodic, +5 authors, Jennifer N Choi.
JAMA Dermatol, 2016 Jul 14; 152(10). PMID: 27411054    Free PMC article.
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
Angel Qin, David G Coffey, Edus H Warren, Nithya Ramnath.
Cancer Med, 2016 Jul 16; 5(9). PMID: 27416962    Free PMC article.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Julie N Graff, Joshi J Alumkal, +8 authors, Tomasz M Beer.
Oncotarget, 2016 Jul 19; 7(33). PMID: 27429197    Free PMC article.
Highly Cited.
Metastatic melanoma and immunotherapy.
Benjamin Herzberg, David E Fisher.
Clin Immunol, 2016 Jul 20; 172. PMID: 27430520    Free PMC article.
Targeted therapies and immunotherapy in non-small-cell lung cancer.
D Cortinovis, M Abbate, +2 authors, S Canova.
Ecancermedicalscience, 2016 Jul 20; 10. PMID: 27433281    Free PMC article.
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Anna Sophie Berghoff, Gerda Ricken, +6 authors, Matthias Preusser.
J Neurooncol, 2016 Oct 21; 130(1). PMID: 27436101
Cancer immunotherapy trials: leading a paradigm shift in drug development.
Leisha A Emens, Lisa H Butterfield, +2 authors, Howard L Kaufman.
J Immunother Cancer, 2016 Jul 21; 4. PMID: 27437105    Free PMC article.
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
Lik Hang Lee, Marcela S Cavalcanti, +12 authors, Jinru Shia.
Mod Pathol, 2016 Oct 28; 29(11). PMID: 27443512    Free PMC article.
Highly Cited.
Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.
Ángela Marrugal, Laura Ojeda, +2 authors, Irene Ferrer.
Dis Markers, 2016 Jul 23; 2016. PMID: 27445423    Free PMC article.
PD-L1 expression is associated with advanced non-small cell lung cancer.
Zhiquan Chen, Jiandong Mei, +6 authors, Liu Zhang.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446371    Free PMC article.
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.
Zhongfu Mo, Jing Liu, +7 authors, Zongbing You.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446374    Free PMC article.
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.
Michael Hettich, Friederike Braun, +2 authors, Gabriele Niedermann.
Theranostics, 2016 Jul 23; 6(10). PMID: 27446497    Free PMC article.
Highly Cited.
PD-1 blockade enhances the vaccination-induced immune response in glioma.
Joseph P Antonios, Horacio Soto, +9 authors, Robert M Prins.
JCI Insight, 2016 Jul 28; 1(10). PMID: 27453950    Free PMC article.
Highly Cited.
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Pratistha Koirala, Michael E Roth, +8 authors, Richard Gorlick.
Sci Rep, 2016 Jul 28; 6. PMID: 27456063    Free PMC article.
Highly Cited.
Chemotherapy remains an essential element of personalized care for persons with lung cancers.
M D Hellmann, B T Li, J E Chaft, M G Kris.
Ann Oncol, 2016 Jul 28; 27(10). PMID: 27456296    Free PMC article.
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458525    Free PMC article.
Immuno-oncology combinations: raising the tail of the survival curve.
Samuel J Harris, Jessica Brown, Juanita Lopez, Timothy A Yap.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458526    Free PMC article.
An update on clinical oncology for the non-oncologist.
Rafael Aliosha Kaliks.
Einstein (Sao Paulo), 2016 Jul 28; 14(2). PMID: 27462901    Free PMC article.
Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion.
Eunseon Ahn, Ben Youngblood, +3 authors, Rafi Ahmed.
J Virol, 2016 Jul 29; 90(19). PMID: 27466420    Free PMC article.
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Andreas H Scheel, Sascha Ansén, +14 authors, Jürgen Wolf.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467949    Free PMC article.
Molecular Imaging of Immunotherapy Targets in Cancer.
Emily B Ehlerding, Christopher G England, Douglas G McNeel, Weibo Cai.
J Nucl Med, 2016 Jul 30; 57(10). PMID: 27469363    Free PMC article.
Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.
Mark Kriegsmann, Rita Casadonte, +7 authors, Wilko Weichert.
Mol Cell Proteomics, 2016 Jul 31; 15(10). PMID: 27473201    Free PMC article.
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Vassiliki Papadimitrakopoulou, J Jack Lee, +25 authors, Roy S Herbst.
J Clin Oncol, 2016 Aug 03; 34(30). PMID: 27480147    Free PMC article.
Highly Cited.
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Raffaele Califano, Keith Kerr, +4 authors, Antonio Rossi.
Curr Oncol Rep, 2016 Aug 04; 18(9). PMID: 27484062
Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.
Benedetto Farsaci, Renee N Donahue, +9 authors, Jeffrey Schlom.
Cancer Immunol Res, 2016 Aug 04; 4(9). PMID: 27485137    Free PMC article.
Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Jinhyun Cho, Soomin Ahn, +4 authors, Jeeyun Lee.
Invest New Drugs, 2016 Aug 06; 34(6). PMID: 27491654
[Pathology of lung cancer].
D Theegarten, T Hager.
Radiologe, 2016 Aug 09; 56(9). PMID: 27495784
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
Yan Yang, Liren Ding, Pingli Wang.
J Thorac Dis, 2016 Aug 09; 8(7). PMID: 27499991    Free PMC article.
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
A H Scheel, M Dietel, +12 authors, R Büttner.
Pathologe, 2016 Oct 28; 37(6). PMID: 27510417
Regulatory circuits of T cell function in cancer.
Daniel E Speiser, Ping-Chih Ho, Grégory Verdeil.
Nat Rev Immunol, 2016 Aug 17; 16(10). PMID: 27526640
Highly Cited. Review.
It's TIME for a biomarker-driven approach to cancer immunotherapy.
Leisha A Emens.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532018    Free PMC article.
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg, Naiyer A Rizvi.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532023    Free PMC article.
Highly Cited. Review.
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Alain P Algazi, Katy K Tsai, +13 authors, Ryan J Sullivan.
Cancer, 2016 Oct 21; 122(21). PMID: 27533448    Free PMC article.
Highly Cited.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534574    Free PMC article.
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Mizuki Nishino, Nikhil H Ramaiya, +7 authors, F Stephen Hodi.
Clin Cancer Res, 2016 Aug 19; 22(24). PMID: 27535979    Free PMC article.
Highly Cited.
New targeted treatments for non-small-cell lung cancer - role of nivolumab.
Giulia Zago, Mirte Muller, Michel van den Heuvel, Paul Baas.
Biologics, 2016 Aug 19; 10. PMID: 27536062    Free PMC article.
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.
Patricia Gaule, James W Smithy, +7 authors, David L Rimm.
JAMA Oncol, 2016 Aug 20; 3(2). PMID: 27541827    Free PMC article.
Highly Cited.
HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Haiying Cheng, Murali Janakiram, +7 authors, Xingxing Zang.
Clin Cancer Res, 2016 Aug 25; 23(3). PMID: 27553831    Free PMC article.
Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.
Lester J Layfield, Sinchita Roy-Chowdhuri, +9 authors, Paul A VanderLaan.
Diagn Cytopathol, 2016 Aug 27; 44(12). PMID: 27561242    Free PMC article.
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.
Marius Ilie, Alexander T Falk, +12 authors, Paul Hofman.
Mod Pathol, 2016 Aug 27; 29(12). PMID: 27562497
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.
Samer Tabchi, Hampig Raphael Kourie, Joseph Kattan.
Invest New Drugs, 2016 Aug 27; 34(6). PMID: 27562868
DNA damage, tumor mutational load and their impact on immune responses against cancer.
Michalis Liontos, Ioannis Anastasiou, Aristotelis Bamias, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563651    Free PMC article.
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.
Jessica Menis, Saskia Litière, Konstantinos Tryfonidis, Vassilis Golfinopoulos.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563654    Free PMC article.
Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.
Giannis Mountzios, Helena Linardou, Paris Kosmidis.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563655    Free PMC article.
Toxicity management of immunotherapy for patients with metastatic melanoma.
Helena Linardou, Helen Gogas.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563659    Free PMC article.
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Kazuhiko Shien, Vassiliki A Papadimitrakopoulou, Ignacio I Wistuba.
Lung Cancer, 2016 Aug 28; 99. PMID: 27565919    Free PMC article.
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
Jeroen de Filette, Yanina Jansen, +4 authors, Bert Bravenboer.
J Clin Endocrinol Metab, 2016 Nov 05; 101(11). PMID: 27571185    Free PMC article.
Highly Cited.
Crizotinib resistance: implications for therapeutic strategies.
I Dagogo-Jack, A T Shaw.
Ann Oncol, 2016 Aug 31; 27 Suppl 3. PMID: 27573756    Free PMC article.
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.
Hazem El-Osta, Kamran Shahid, Glenn M Mills, Prakash Peddi.
Onco Targets Ther, 2016 Aug 31; 9. PMID: 27574451    Free PMC article.
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Brandon S Sheffield, Regan Fulton, +15 authors, Diana N Ionescu.
J Histochem Cytochem, 2016 Sep 04; 64(10). PMID: 27591097    Free PMC article.
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.
Richard Beatson, Virginia Tajadura-Ortega, +9 authors, Joy M Burchell.
Nat Immunol, 2016 Oct 21; 17(11). PMID: 27595232    Free PMC article.
Highly Cited.
Monitoring of the Immune Dysfunction in Cancer Patients.
Saskia J A M Santegoets, Marij J P Welters, Sjoerd H van der Burg.
Vaccines (Basel), 2016 Sep 07; 4(3). PMID: 27598210    Free PMC article.
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Jeffrey C Thompson, Stephanie S Yee, +19 authors, Erica L Carpenter.
Clin Cancer Res, 2016 Sep 08; 22(23). PMID: 27601595    Free PMC article.
Highly Cited.
Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report.
Rong Pu, Qianhong Zhao, +5 authors, Xianyong Li.
Oncol Lett, 2016 Sep 08; 12(3). PMID: 27602132    Free PMC article.
[Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
C-J Busch, S Laban, R Knecht, T K Hoffmann.
HNO, 2016 Sep 09; 64(10). PMID: 27604282
Immunotherapy in human colorectal cancer: Challenges and prospective.
Xuan Sun, Jian Suo, Jun Yan.
World J Gastroenterol, 2016 Sep 09; 22(28). PMID: 27605872    Free PMC article.
Advances in lung cancer with a focus on ATS 2016 updates.
Jinghong Li, Mark M Fuster.
J Thorac Dis, 2016 Sep 09; 8(Suppl 7). PMID: 27606096    Free PMC article.
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
Rikke B Holmgaard, Alexandra Brachfeld, +7 authors, Taha Merghoub.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622016    Free PMC article.
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chang-Long Chen, Qiu-Zhong Pan, +12 authors, Jian-Chuan Xia.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622026    Free PMC article.
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Roch Houot, Philippe Gaulard, +18 authors, Daniel Olive.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622041    Free PMC article.
Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.
Martin G Klatt, Daniel J Kowalewski, +5 authors, Stefan Stevanović.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622074    Free PMC article.
[Immunotherapy for HNSCC : Quo vadis?].
J Döscher, C-J Busch, P J Schuler, S Laban.
HNO, 2016 Sep 15; 64(10). PMID: 27624904
Update in Lung Cancer 2015.
Avrum Spira, Balazs Halmos, Charles A Powell.
Am J Respir Crit Care Med, 2016 Sep 16; 194(6). PMID: 27628077    Free PMC article.
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Akihito Kawazoe, Takeshi Kuwata, +7 authors, Atsushi Ochiai.
Gastric Cancer, 2016 Sep 16; 20(3). PMID: 27629881
Highly Cited.
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Hui Yu, Cory Batenchuk, +23 authors, Fred R Hirsch.
J Thorac Oncol, 2016 Oct 25; 12(1). PMID: 27639678    Free PMC article.
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, +26 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Sep 21; 35(7). PMID: 27646942    Free PMC article.
Highly Cited.
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Laura Q M Chow, Robert Haddad, +19 authors, Tanguy Y Seiwert.
J Clin Oncol, 2016 Sep 21; 34(32). PMID: 27646946    Free PMC article.
Highly Cited.
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Yu Mei, Wenya Linda Bi, +11 authors, Ian F Dunn.
Oncotarget, 2016 Sep 23; 7(47). PMID: 27655724    Free PMC article.
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Archana Anantharaman, Terence Friedlander, +14 authors, Pamela L Paris.
BMC Cancer, 2016 Sep 24; 16(1). PMID: 27658492    Free PMC article.
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis.
Rubens Chang, Keisuke Shirai.
BMJ Case Rep, 2016 Sep 24; 2016. PMID: 27659911    Free PMC article.
Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.
Yeonjoo Choi, Jin Won Kim, +7 authors, Hyung-Ho Kim.
Gastric Cancer, 2016 Sep 26; 20(4). PMID: 27665104
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Tengfei Zhang, Jing Xie, +13 authors, Yi Zhang.
Oncotarget, 2016 Sep 30; 7(45). PMID: 27683031    Free PMC article.
Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.
Damian T Rieke, Sebastian Ochsenreither, +4 authors, Ulrich Keilholz.
Oncotarget, 2016 Sep 30; 7(46). PMID: 27683114    Free PMC article.
Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.
Charli Dominguez, Kwong-Yok Tsang, Claudia Palena.
Cell Death Dis, 2016 Sep 30; 7(9). PMID: 27685624    Free PMC article.
Trends and advances in tumor immunology and lung cancer immunotherapy.
Mohanad Aldarouish, Cailian Wang.
J Exp Clin Cancer Res, 2016 Oct 01; 35(1). PMID: 27686848    Free PMC article.
Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?
Fabienne McClanahan, Thomas G Sharp, John G Gribben.
Haematologica, 2016 Oct 04; 101(10). PMID: 27694502    Free PMC article.
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
Peter E Clark, Philippe E Spiess, +33 authors, Courtney Smith.
J Natl Compr Canc Netw, 2016 Oct 05; 14(10). PMID: 27697976    Free PMC article.
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.
Patrick H Lizotte, Elena V Ivanova, +23 authors, Kwok-Kin Wong.
JCI Insight, 2016 Oct 05; 1(14). PMID: 27699239    Free PMC article.
Highly Cited.
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date.
Pankit Vachhani, Hongbin Chen.
Onco Targets Ther, 2016 Oct 08; 9. PMID: 27713639    Free PMC article.
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Tadanobu Nagaya, Yuko Nakamura, +5 authors, Hisataka Kobayashi.
Oncotarget, 2016 Oct 08; 8(5). PMID: 27716622    Free PMC article.
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Marlon C Rebelatto, Anita Midha, +8 authors, Jill Walker.
Diagn Pathol, 2016 Oct 09; 11(1). PMID: 27717372    Free PMC article.
Highly Cited.
Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.
Xi Zhang, Yuge Ran, +2 authors, Jinghua Li.
Drug Des Devel Ther, 2016 Oct 13; 10. PMID: 27729774    Free PMC article.
Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Hyeyoon Chang, Woon Yong Jung, +5 authors, Baek-Hui Kim.
Oncotarget, 2016 Oct 16; 7(49). PMID: 27741514    Free PMC article.
Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Adepitan A Owosho, Joseph Randazzo, +4 authors, SaeHee K Yom.
Oral Oncol, 2016 Oct 17; 63. PMID: 27743938    Free PMC article.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Corey J Langer, Shirish M Gadgeel, +17 authors, KEYNOTE-021 investigators.
Lancet Oncol, 2016 Oct 18; 17(11). PMID: 27745820    Free PMC article.
Highly Cited.
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.
Manojkumar Bupathi, Christina Wu.
J Gastrointest Oncol, 2016 Oct 18; 7(5). PMID: 27747085    Free PMC article.
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.
Zhaohui Jin, Harry H Yoon.
J Gastrointest Oncol, 2016 Oct 18; 7(5). PMID: 27747091    Free PMC article.
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.
Gustavo Dix Junqueira Pinto, Luciano de Souza Viana, Cristovam Scapulatempo Neto, Sérgio Vicente Serrano.
J Immunol Res, 2016 Oct 18; 2016. PMID: 27747247    Free PMC article.
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
Nageatte Ibrahim, Elizabeth I Buchbinder, +7 authors, F Stephen Hodi.
Cancer Med, 2016 Oct 18; 5(11). PMID: 27748045    Free PMC article.
Trial Watch: Immunotherapy plus radiation therapy for oncological indications.
Erika Vacchelli, Norma Bloy, +13 authors, Lorenzo Galluzzi.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757313    Free PMC article.
[Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Shouzheng Wang, Junling Li.
Zhongguo Fei Ai Za Zhi, 2016 Oct 21; 19(10). PMID: 27760599    Free PMC article.
Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.
Ana M Contreras-Sandoval, María Merino, +3 authors, María J Garrido.
Oncotarget, 2016 Oct 21; 7(47). PMID: 27764774    Free PMC article.
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
Ettore D'Argento, Sabrina Rossi, +4 authors, Carlo Barone.
Curr Treat Options Oncol, 2016 Oct 22; 17(12). PMID: 27766545
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
Taofeek K Owonikoko, Mukesh Kumar, +10 authors, Suresh S Ramalingam.
Cancer Immunol Immunother, 2016 Oct 25; 66(1). PMID: 27771741    Free PMC article.
Multiplatform-based molecular subtypes of non-small-cell lung cancer.
F Chen, Y Zhang, +9 authors, C J Creighton.
Oncogene, 2016 Oct 25; 36(10). PMID: 27775076    Free PMC article.
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.
Bridgette A Kanz, Megan H Pollack, +8 authors, Douglas B Johnson.
J Immunother Cancer, 2016 Oct 26; 4. PMID: 27777770    Free PMC article.
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
Hyerim Ha, Ah-Rong Nam, +8 authors, Do-Youn Oh.
Oncotarget, 2016 Oct 27; 7(47). PMID: 27780932    Free PMC article.
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Ju Yeon Lee, Hyun Tae Lee, +11 authors, Yong-Seok Heo.
Nat Commun, 2016 Nov 01; 7. PMID: 27796306    Free PMC article.
Highly Cited.
Lung Cancer Subtypes Generate Unique Immune Responses.
Stephanie E Busch, Mark L Hanke, +3 authors, A McGarry Houghton.
J Immunol, 2016 Nov 02; 197(11). PMID: 27799309    Free PMC article.
Checkpoint inhibitors in lung cancer: latest developments and clinical potential.
Gustavo Schvartsman, Renata Ferrarotto, Erminia Massarelli.
Ther Adv Med Oncol, 2016 Nov 02; 8(6). PMID: 27800034    Free PMC article.
Recent advances in understanding antitumor immunity.
Rodrigo Ramella Munhoz, Michael Andrew Postow.
F1000Res, 2016 Nov 03; 5. PMID: 27803807    Free PMC article.
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Aaron Goodman, Sandip P Patel, Razelle Kurzrock.
Nat Rev Clin Oncol, 2016 Nov 03; 14(4). PMID: 27805626
Highly Cited. Review.
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Andrea Botticelli, Ilaria Zizzari, +6 authors, Paolo Marchetti.
Oncotarget, 2016 Nov 03; 8(5). PMID: 27806346    Free PMC article.
Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Ann Margaret V Chang, Simion I Chiosea, +2 authors, Changqing Ma.
Head Neck Pathol, 2016 Nov 04; 11(2). PMID: 27807760    Free PMC article.
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Shuguang Tan, Danqing Chen, +9 authors, George F Gao.
Protein Cell, 2016 Nov 07; 7(12). PMID: 27815822    Free PMC article.
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Yu-Mu Chen, Chien-Hao Lai, +15 authors, Meng-Chih Lin.
BMC Cancer, 2016 Nov 09; 16(1). PMID: 27821111    Free PMC article.
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Wei Xue, Victoria A Brentville, +4 authors, Lindy G Durrant.
Oncotarget, 2016 Nov 09; 7(50). PMID: 27825115    Free PMC article.
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
Wolfram C M Dempke, Klaus Fenchel.
Transl Lung Cancer Res, 2016 Nov 09; 5(5). PMID: 27826536    Free PMC article.
Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.
Emilie Bousquet, Allison Zarbo, +4 authors, Vincent Sibaud.
Acta Derm Venereol, 2016 Nov 09; 97(4). PMID: 27826614    Free PMC article.
Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity.
Tony T Jiang, Tijana Martinov, +4 authors, Sing Sing Way.
Cell Rep, 2016 Nov 10; 17(7). PMID: 27829150    Free PMC article.
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.
Ana P S Silva, Priscila V Coelho, Maristella Anazetti, Patricia U Simioni.
Hum Vaccin Immunother, 2016 Nov 11; 13(4). PMID: 27831000    Free PMC article.
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Jamaal A Rehman, Gang Han, +6 authors, David L Rimm.
Mod Pathol, 2016 Nov 12; 30(3). PMID: 27834350    Free PMC article.
Highly Cited.
Gene-expression profiling to predict responsiveness to immunotherapy.
N B Jamieson, A V Maker.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834354    Free PMC article.
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Maarten Swart, Inge Verbrugge, Joost B Beltman.
Front Oncol, 2016 Nov 17; 6. PMID: 27847783    Free PMC article.
Highly Cited. Review.
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
Ricardo Costa, Benedito A Carneiro, +6 authors, Francis J Giles.
Oncotarget, 2016 Nov 17; 8(5). PMID: 27852042    Free PMC article.
Systematic Review.
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Kent W Mouw, James M Cleary, +16 authors, Alan D D'Andrea.
Clin Cancer Res, 2016 Nov 18; 23(12). PMID: 27852700    Free PMC article.
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Yayan T Sundara, Marie Kostine, +3 authors, Anne-Marie Cleton-Jansen.
Cancer Immunol Immunother, 2016 Nov 18; 66(1). PMID: 27853827    Free PMC article.
Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.
J Elassaiss-Schaap, S Rossenu, +4 authors, D P de Alwis.
CPT Pharmacometrics Syst Pharmacol, 2016 Nov 20; 6(1). PMID: 27863143    Free PMC article.
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Adil I Daud, Jedd D Wolchok, +21 authors, Omid Hamid.
J Clin Oncol, 2016 Nov 20; 34(34). PMID: 27863197    Free PMC article.
Highly Cited.
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
B Bonavida, S Chouaib.
Ann Oncol, 2016 Nov 20; 28(3). PMID: 27864216    Free PMC article.
Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches.
Valentina Mazza, Federico Cappuzzo.
J Thorac Dis, 2016 Nov 22; 8(10). PMID: 27867624    Free PMC article.
Next generation predictive biomarkers for immune checkpoint inhibition.
Yulian Khagi, Razelle Kurzrock, Sandip Pravin Patel.
Cancer Metastasis Rev, 2016 Nov 23; 36(1). PMID: 27873079    Free PMC article.
Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
Jasna Aleksova, Peter K H Lau, Georgia Soldatos, Grant McArthur.
BMJ Case Rep, 2016 Nov 25; 2016. PMID: 27881588    Free PMC article.
Advances in Cancer Immunotherapy in Solid Tumors.
Smitha Menon, Sarah Shin, Grace Dy.
Cancers (Basel), 2016 Nov 26; 8(12). PMID: 27886124    Free PMC article.
Highly Cited. Review.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Kevin K Dobbin, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 29; 4. PMID: 27891226    Free PMC article.
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Paul W Sperduto, T Jonathan Yang, +24 authors, Minesh P Mehta.
JAMA Oncol, 2016 Nov 29; 3(6). PMID: 27892978    Free PMC article.
Highly Cited.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Giuseppe V Masucci, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 30; 4. PMID: 27895917    Free PMC article.
Highly Cited. Review.
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
M S Chatterjee, J Elassaiss-Schaap, +9 authors, D P de Alwis.
CPT Pharmacometrics Syst Pharmacol, 2016 Nov 30; 6(1). PMID: 27896938    Free PMC article.
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.
Stefan Gröschel, Martin Bommer, +20 authors, Stefan Fröhling.
Cold Spring Harb Mol Case Stud, 2016 Dec 03; 2(6). PMID: 27900363    Free PMC article.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, +24 authors, Antoni Ribas.
Cancer Discov, 2016 Dec 03; 7(2). PMID: 27903500    Free PMC article.
Highly Cited.
What does PD-L1 positive or negative mean?
Antoni Ribas, Siwen Hu-Lieskovan.
J Exp Med, 2016 Dec 03; 213(13). PMID: 27903604    Free PMC article.
Highly Cited. Review.
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.
Benjamin E Paluch, Sean T Glenn, +14 authors, Carl D Morrison.
Oncotarget, 2016 Dec 03; 8(2). PMID: 27911273    Free PMC article.
Lung Cancer Biomarkers.
Pamela Villalobos, Ignacio I Wistuba.
Hematol Oncol Clin North Am, 2016 Dec 04; 31(1). PMID: 27912828    Free PMC article.
Pharmacological and immunological targeting of tumor mesenchymalization.
Justin M David, Charli Dominguez, Claudia Palena.
Pharmacol Ther, 2016 Dec 06; 170. PMID: 27916651    Free PMC article.
First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation.
Johann von Felden, Kornelius Schulze, +2 authors, Henning Wege.
Diagnostics (Basel), 2016 Dec 06; 6(4). PMID: 27916795    Free PMC article.
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Tianhong Li, Bilal Piperdi, +14 authors, Roman Perez-Soler.
Clin Lung Cancer, 2016 Dec 07; 18(1). PMID: 27919627    Free PMC article.
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Mariko Hirai, Hiroko Kitahara, +4 authors, Shuichi Kawashiri.
Int J Oncol, 2016 Dec 07; 50(1). PMID: 27922697    Free PMC article.
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Geoffrey T Gibney, Louis M Weiner, Michael B Atkins.
Lancet Oncol, 2016 Dec 08; 17(12). PMID: 27924752    Free PMC article.
Highly Cited. Review.
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.
Edward B Garon, Jeffrey D Neidhart, +3 authors, Fairooz Kabbinavar.
Onco Targets Ther, 2016 Dec 13; 9. PMID: 27942221    Free PMC article.
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.
Sadakatsu Ikeda, Aaron M Goodman, +6 authors, Razelle Kurzrock.
NPJ Genom Med, 2016 Dec 13; 1. PMID: 27942391    Free PMC article.
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.
Tavi Nathanson, Arun Ahuja, +8 authors, Jeff Hammerbacher.
Cancer Immunol Res, 2016 Dec 14; 5(1). PMID: 27956380    Free PMC article.
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond.
Mack Y Su, David E Fisher.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959922    Free PMC article.
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Stephen J Luen, Roberto Salgado, +8 authors, Sherene Loi.
Lancet Oncol, 2016 Dec 15; 18(1). PMID: 27964843    Free PMC article.
Highly Cited.
Innate immune signaling and regulation in cancer immunotherapy.
Leticia Corrales, Vyara Matson, +2 authors, Thomas F Gajewski.
Cell Res, 2016 Dec 17; 27(1). PMID: 27981969    Free PMC article.
Highly Cited. Review.
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
Bob T Li, Tristan A Barnes, +9 authors, Nick Pavlakis.
Lung Cancer, 2016 Dec 19; 102. PMID: 27987583    Free PMC article.
Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
C L Haddox, N Shenoy, +5 authors, M P Goetz.
Ann Oncol, 2016 Dec 21; 28(3). PMID: 27993808    Free PMC article.
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.
M Kudo.
Liver Cancer, 2016 Dec 21; 6(1). PMID: 27995082    Free PMC article.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon.
Target Oncol, 2016 Dec 21; 12(2). PMID: 27995439
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
J C Osorio, A Ni, +11 authors, M D Hellmann.
Ann Oncol, 2016 Dec 22; 28(3). PMID: 27998967    Free PMC article.
Highly Cited.
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
Valérie Dutoit, Denis Migliorini, Pierre-Yves Dietrich, Paul R Walker.
Front Oncol, 2016 Dec 23; 6. PMID: 28003994    Free PMC article.
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine.
Masayuki Nagahashi, Toshifumi Wakai, +25 authors, Stephen Lyle.
Genome Med, 2016 Dec 23; 8(1). PMID: 28007036    Free PMC article.
Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer.
Quoc-Anh Ho, Nima K Harandi, Megan E Daly.
Clin Lung Cancer, 2016 Dec 23; 18(4). PMID: 28007410    Free PMC article.
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
Kankana Bardhan, Theodora Anagnostou, Vassiliki A Boussiotis.
Front Immunol, 2016 Dec 27; 7. PMID: 28018338    Free PMC article.
Highly Cited. Review.
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.
Mizuki Nishino, Nikhil H Ramaiya, +5 authors, Mark M Awad.
J Immunother Cancer, 2016 Dec 27; 4. PMID: 28018599    Free PMC article.
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Kellie N Smith, +26 authors, Victor E Velculescu.
Cancer Discov, 2016 Dec 30; 7(3). PMID: 28031159    Free PMC article.
Highly Cited.
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
Marc C Chamberlain, Christina S Baik, +2 authors, Laura Q M Chow.
Neuro Oncol, 2016 Dec 30; 19(1). PMID: 28031389    Free PMC article.
Potential role of immunotherapy in advanced non-small-cell lung cancer.
Ramon Andrade de Mello, Ana Flávia Veloso, +2 authors, Georgios Antoniou.
Onco Targets Ther, 2016 Dec 30; 10. PMID: 28031719    Free PMC article.
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Xiao-Yi Tang, Yao Sun, +5 authors, Hu Chen.
BMJ Open, 2017 Jan 01; 6(12). PMID: 28039295    Free PMC article.
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Dongxian Jiang, Qi Song, +9 authors, Yingyong Hou.
Oncotarget, 2017 Jan 01; 8(5). PMID: 28039448    Free PMC article.
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
W Joost Lesterhuis, Anthony Bosco, +3 authors, Richard A Lake.
Nat Rev Drug Discov, 2017 Jan 07; 16(4). PMID: 28057932
Highly Cited. Review.
Programmed death-ligand 1 expression in rectal cancer.
G Jomrich, G R Silberhumer, +2 authors, L Müllauer.
Eur Surg, 2017 Jan 07; 48(6). PMID: 28058043    Free PMC article.
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.
Georg Hutarew.
Memo, 2017 Jan 07; 9(4). PMID: 28058063    Free PMC article.
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Thomas J Gniadek, Qing Kay Li, +3 authors, Edward Gabrielson.
Mod Pathol, 2017 Jan 07; 30(4). PMID: 28059094
The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.
Shona A Hendry, Rae H Farnsworth, +3 authors, Stephen B Fox.
Front Immunol, 2017 Jan 10; 7. PMID: 28066431    Free PMC article.
Highly Cited. Review.
PD-L1 expression in lung cancer.
Chad Tang, Joe Y Chang.
J Thorac Dis, 2017 Jan 10; 8(11). PMID: 28066581    Free PMC article.
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger.
Cell Commun Signal, 2017 Jan 12; 15(1). PMID: 28073373    Free PMC article.
Highly Cited. Review.
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Takuro Noguchi, Jeffrey P Ward, +8 authors, Robert D Schreiber.
Cancer Immunol Res, 2017 Jan 12; 5(2). PMID: 28073774    Free PMC article.
Highly Cited.
Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Atiqullah Aziz, Jakub Dobruch, +11 authors, Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.
World J Urol, 2017 Jan 12; 35(9). PMID: 28074261
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
Victor Prima, Lyudmila N Kaliberova, +2 authors, Sergei Kusmartsev.
Proc Natl Acad Sci U S A, 2017 Jan 18; 114(5). PMID: 28096371    Free PMC article.
Highly Cited.
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.
Tom L Stephen, Kyle K Payne, +11 authors, Jose R Conejo-Garcia.
Immunity, 2017 Jan 19; 46(1). PMID: 28099864    Free PMC article.
Highly Cited.
Elements of cancer immunity and the cancer-immune set point.
Daniel S Chen, Ira Mellman.
Nature, 2017 Jan 20; 541(7637). PMID: 28102259
Highly Cited. Review.
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Deepa Rangachari, Paul A VanderLaan, +4 authors, Daniel B Costa.
J Thorac Oncol, 2017 Jan 21; 12(5). PMID: 28104537    Free PMC article.
Highly Cited.
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
David J Byun, Jedd D Wolchok, Lynne M Rosenberg, Monica Girotra.
Nat Rev Endocrinol, 2017 Jan 21; 13(4). PMID: 28106152    Free PMC article.
Highly Cited. Review.
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114250    Free PMC article.
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Joseph P Antonios, Horacio Soto, +12 authors, Robert M Prins.
Neuro Oncol, 2017 Jan 25; 19(6). PMID: 28115578    Free PMC article.
Highly Cited.
Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.
Hui Zhang, Ryu Watanabe, +5 authors, Cornelia M Weyand.
Proc Natl Acad Sci U S A, 2017 Jan 25; 114(6). PMID: 28115719    Free PMC article.
Highly Cited.
Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy.
Hidenobu Ishii, Koichi Azuma, +5 authors, Tomoaki Hoshino.
BMJ Open Respir Res, 2017 Jan 27; 4(1). PMID: 28123750    Free PMC article.
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
Henoch S Hong, Sven D Koch, +9 authors, James M Billingsley.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123889    Free PMC article.
Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.
Romain Remark, Audrey Lupo, +8 authors, Diane Damotte.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123901    Free PMC article.
Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report.
R Kuint, M Lotem, +5 authors, Z G Fridlender.
Respir Med Case Rep, 2017 Jan 28; 20. PMID: 28127529    Free PMC article.
PD-L1 Expression in Pancreatic Cancer.
Lei Zheng.
J Natl Cancer Inst, 2017 Jan 31; 109(6). PMID: 28131993    Free PMC article.
Medication-associated gastrointestinal tract injury.
Michael Vieth, Elizabeth Montgomery.
Virchows Arch, 2017 Jan 31; 470(3). PMID: 28133700
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.
Jennifer L Kalina, David S Neilson, +4 authors, Julian J Lum.
Cancers (Basel), 2017 Jan 31; 9(2). PMID: 28134800    Free PMC article.
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
M-S Tsao, G Le Teuff, +11 authors, E Brambilla.
Ann Oncol, 2017 Feb 01; 28(4). PMID: 28137741    Free PMC article.
Highly Cited.
The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
David A Reardon, Duane A Mitchell.
Semin Immunopathol, 2017 Feb 01; 39(2). PMID: 28138787
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Shafei Wu, Xiaohua Shi, +5 authors, Xuan Zeng.
Oncotarget, 2017 Feb 02; 8(10). PMID: 28145884    Free PMC article.
Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.
Elma Kadić, Raymond J Moniz, +2 authors, Ilona Kariv.
BMC Immunol, 2017 Feb 06; 18(1). PMID: 28148223    Free PMC article.
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.
Grainne M O'Kane, Natasha B Leighl.
Transl Lung Cancer Res, 2017 Feb 06; 5(6). PMID: 28149757    Free PMC article.
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
Chul Kim, Arun Rajan, Pedro A DeBrito, Giuseppe Giaccone.
Transl Lung Cancer Res, 2017 Feb 06; 5(6). PMID: 28149767    Free PMC article.
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.
Sawsan Rashdan, David E Gerber.
Ann Transl Med, 2017 Feb 06; 4(24). PMID: 28149890    Free PMC article.
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Takeru Asano, Yusuke Meguri, +17 authors, Ken-Ichi Matsuoka.
Blood, 2017 Feb 06; 129(15). PMID: 28151427    Free PMC article.
Highly Cited.
Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.
Reid W Merryman, Philippe Armand.
Curr Hematol Malig Rep, 2017 Feb 06; 12(1). PMID: 28155012
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Shuguang Tan, Hao Zhang, +13 authors, Jinghua Yan.
Nat Commun, 2017 Feb 07; 8. PMID: 28165004    Free PMC article.
Highly Cited.
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, +15 authors, Mien-Chie Hung.
Clin Cancer Res, 2017 Feb 09; 23(14). PMID: 28167507    Free PMC article.
Highly Cited.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
DNA vaccines for prostate cancer.
Christopher D Zahm, Viswa Teja Colluru, Douglas G McNeel.
Pharmacol Ther, 2017 Feb 12; 174. PMID: 28185916    Free PMC article.
Applications of Immunogenomics to Cancer.
X Shirley Liu, Elaine R Mardis.
Cell, 2017 Feb 12; 168(4). PMID: 28187283    Free PMC article.
Highly Cited. Review.
Renal complications of immune checkpoint blockade.
Naoka Murakami, Shveta Motwani, Leonardo V Riella.
Curr Probl Cancer, 2017 Feb 13; 41(2). PMID: 28189263    Free PMC article.
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.
Shu Su, Zhengyun Zou, +12 authors, Baorui Liu.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197365    Free PMC article.
Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.
Duane H Hamilton, Justin M David, Charli Dominguez, Claudia Palena.
Cells Tissues Organs, 2017 Feb 20; 203(2). PMID: 28214895    Free PMC article.
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
Maria Rita Migliorino, Antonio Santo, +13 authors, Filippo de Marinis.
J Cancer Res Clin Oncol, 2017 Feb 20; 143(5). PMID: 28215027
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Janet Lau, Jeanne Cheung, +17 authors, Maike Schmidt.
Nat Commun, 2017 Feb 22; 8. PMID: 28220772    Free PMC article.
Highly Cited.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, +9 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2017 Feb 23; 23(15). PMID: 28223273    Free PMC article.
[Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
Zhansheng Jiang, Zhanyu Pan, Xiubao Ren.
Zhongguo Fei Ai Za Zhi, 2017 Feb 24; 20(2). PMID: 28228226    Free PMC article.
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
Andreas D Hartkopf, Florin-Andrei Taran, +4 authors, Sara Y Brucker.
Breast Care (Basel), 2017 Feb 24; 11(6). PMID: 28228704    Free PMC article.
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Vivek Kumar, Neha Chaudhary, +3 authors, Abhinav B Chandra.
Front Pharmacol, 2017 Feb 24; 8. PMID: 28228726    Free PMC article.
Highly Cited. Review.
Targeting neoantigens to augment antitumour immunity.
Mark Yarchoan, Burles A Johnson, +2 authors, Elizabeth M Jaffee.
Nat Rev Cancer, 2017 Feb 25; 17(4). PMID: 28233802    Free PMC article.
Highly Cited. Review.
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Eileen Shiuan, Kathryn E Beckermann, +11 authors, Douglas Johnson.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239462    Free PMC article.
Combination immunotherapy: a road map.
Patrick A Ott, F Stephen Hodi, +2 authors, Jedd D Wolchok.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239469    Free PMC article.
Highly Cited. Review.
Targeting the programmed death-1 pathway in lymphoid neoplasms.
Chi Young Ok, Ken H Young.
Cancer Treat Rev, 2017 Mar 01; 54. PMID: 28242522    Free PMC article.
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.
Joshua A Roth, Bernardo H L Goulart, +2 authors, Scott D Ramsey.
Oncologist, 2017 Mar 01; 22(3). PMID: 28242792    Free PMC article.
Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.
Jens Köhler.
Front Med (Lausanne), 2017 Mar 01; 4. PMID: 28243590    Free PMC article.
A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.
Andrew C Birkeland, Paul L Swiecicki, J Chad Brenner, Andrew G Shuman.
Expert Rev Precis Med Drug Dev, 2016 Jan 01; 1(4). PMID: 28251187    Free PMC article.
Gene signature driving invasive mucinous adenocarcinoma of the lung.
Minzhe Guo, Koichi Tomoshige, +11 authors, Yutaka Maeda.
EMBO Mol Med, 2017 Mar 04; 9(4). PMID: 28255028    Free PMC article.
Emerging challenges of advanced squamous cell lung cancer.
Yi-Chen Zhang, Qing Zhou, Yi-Long Wu.
ESMO Open, 2017 Mar 04; 1(6). PMID: 28255454    Free PMC article.
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Andrew S Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim.
Neurotherapeutics, 2017 Mar 05; 14(4). PMID: 28258545    Free PMC article.
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Liliana E Lucca, David A Hafler.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258696    Free PMC article.
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context.
Alexander D Le, Saeed K Alzghari, Gary W Jean, Ninh M La-Beck.
Ther Clin Risk Manag, 2017 Mar 07; 13. PMID: 28260909    Free PMC article.
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.
Naoya Yamazaki, Yoshio Kiyohara, +11 authors, Hideaki Tahara.
Cancer Sci, 2017 Mar 08; 108(5). PMID: 28266140    Free PMC article.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, +16 authors, RECIST working group.
Lancet Oncol, 2017 Mar 09; 18(3). PMID: 28271869    Free PMC article.
Highly Cited. Review.
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
Yayi He, Leslie Rozeboom, +5 authors, Fred R Hirsch.
Med Sci Monit, 2017 Mar 10; 23. PMID: 28275222    Free PMC article.
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
David L Rimm, Gang Han, +17 authors, Ignacio I Wistuba.
JAMA Oncol, 2017 Mar 10; 3(8). PMID: 28278348    Free PMC article.
Highly Cited.
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Motonobu Saito, Hiroyuki Suzuki, +2 authors, Takashi Kohno.
Surg Today, 2017 Mar 11; 48(1). PMID: 28280984
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Jordi Remon, Benjamin Besse, Jean-Charles Soria.
BMC Med, 2017 Mar 14; 15(1). PMID: 28285592    Free PMC article.
The high price of anticancer drugs: origins, implications, barriers, solutions.
Vinay Prasad, Kevin De Jesús, Sham Mailankody.
Nat Rev Clin Oncol, 2017 Mar 16; 14(6). PMID: 28290490
Highly Cited. Review.
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Ashwin Somasundaram, Timothy F Burns.
Lung Cancer (Auckl), 2017 Mar 16; 8. PMID: 28293123    Free PMC article.
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Wenwen Du, Min Yang, +5 authors, Binfeng Lu.
Int J Mol Sci, 2017 Mar 17; 18(3). PMID: 28300768    Free PMC article.
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer.
Jong Ho Cho, Wei Zhou, +7 authors, Jhingook Kim.
Cancer Res Treat, 2017 Mar 18; 50(1). PMID: 28301925    Free PMC article.
Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment.
Liliana E Lucca, David A Hafler.
J Clin Invest, 2017 Mar 21; 127(4). PMID: 28319049    Free PMC article.
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml, Tanguy Y Seiwert, +15 authors, Robert Haddad.
J Clin Oncol, 2017 Mar 23; 35(14). PMID: 28328302    Free PMC article.
Highly Cited.
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
Laurence P Diggs, Eddy C Hsueh.
Biomark Res, 2017 Mar 24; 5. PMID: 28331612    Free PMC article.
Highly Cited. Review.
Systematic evaluation of immune regulation and modulation.
David F Stroncek, Lisa H Butterfield, +12 authors, Barbara Seliger.
J Immunother Cancer, 2017 Mar 24; 5. PMID: 28331613    Free PMC article.
Development of CAR T cells designed to improve antitumor efficacy and safety.
Janneke E Jaspers, Renier J Brentjens.
Pharmacol Ther, 2017 Mar 28; 178. PMID: 28342824    Free PMC article.
Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.
Paul Nghiem, Howard L Kaufman, +3 authors, Jürgen C Becker.
Future Oncol, 2017 Mar 30; 13(14). PMID: 28350180    Free PMC article.
Systematic Review.
Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
Angel Qin, Lindsay Street, +4 authors, Nithya Ramnath.
Clin Lung Cancer, 2017 Apr 04; 18(5). PMID: 28366756    Free PMC article.
Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.
Toru Kumagai, Madoka Kimura, +3 authors, Fumio Imamura.
Thorac Cancer, 2017 Apr 04; 8(3). PMID: 28371397    Free PMC article.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
James L Gulley, Arun Rajan, +11 authors, Karen Kelly.
Lancet Oncol, 2017 Apr 05; 18(5). PMID: 28373005    Free PMC article.
Highly Cited.
Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer.
Barbara Melosky.
Front Oncol, 2017 Apr 05; 7. PMID: 28373963    Free PMC article.
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
James L Gulley, Ravi A Madan, +4 authors, Charles G Drake.
J Natl Cancer Inst, 2017 Apr 05; 109(4). PMID: 28376158    Free PMC article.
Highly Cited. Review.
Cancer immunotherapies targeting the PD-1 signaling pathway.
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo.
J Biomed Sci, 2017 Apr 06; 24(1). PMID: 28376884    Free PMC article.
Highly Cited. Review.
A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
Zu-Jun Sun, Yi Wu, +4 authors, Min Yu.
Oncotarget, 2017 Apr 14; 8(17). PMID: 28404966    Free PMC article.
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.
Xinru Wei, Yunxin Lai, +17 authors, Peng Li.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405515    Free PMC article.
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
Charu Aggarwal, Hossein Borghaei.
Oncologist, 2017 Apr 15; 22(6). PMID: 28408617    Free PMC article.
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Katrijn Broos, Marleen Keyaerts, +7 authors, Nick Devoogdt.
Oncotarget, 2017 Apr 15; 8(26). PMID: 28410210    Free PMC article.
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Paul C Tumeh, Matthew D Hellmann, +31 authors, Adil Daud.
Cancer Immunol Res, 2017 Apr 16; 5(5). PMID: 28411193    Free PMC article.
Highly Cited.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Wei Ding, Betsy R LaPlant, +32 authors, Stephen M Ansell.
Blood, 2017 Apr 21; 129(26). PMID: 28424162    Free PMC article.
Highly Cited.
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.
Marco A J Iafolla, Rosalyn A Juergens.
Front Oncol, 2017 Apr 22; 7. PMID: 28428947    Free PMC article.
The next generation of immunotherapy: keeping lung cancer in check.
Ashwin Somasundaram, Timothy F Burns.
J Hematol Oncol, 2017 Apr 25; 10(1). PMID: 28434399    Free PMC article.
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Eytan Ben-Ami, Constance M Barysauskas, +15 authors, Suzanne George.
Cancer, 2017 Apr 26; 123(17). PMID: 28440953    Free PMC article.
Highly Cited.
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
Daniel J Boffa, Ryon P Graf, +14 authors, Jorge Nieva.
Cancer Epidemiol Biomarkers Prev, 2017 Apr 28; 26(7). PMID: 28446544    Free PMC article.
Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Yongxun Zhuansun, Fengting Huang, +3 authors, Jianguo Li.
J Thorac Dis, 2017 Apr 30; 9(3). PMID: 28449473    Free PMC article.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
P A Ott, S A Piha-Paul, +13 authors, J Bennouna.
Ann Oncol, 2017 Apr 30; 28(5). PMID: 28453692    Free PMC article.
Highly Cited.
Emerging therapies for breast cancer.
Xichun Hu, Wei Huang, Minhao Fan.
J Hematol Oncol, 2017 Apr 30; 10(1). PMID: 28454587    Free PMC article.
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy.
Hengfeng Yuan, Wen Jiang, +9 authors, Betty Y S Kim.
Nat Nanotechnol, 2017 May 02; 12(8). PMID: 28459470
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Liyan Jiang, Xinying Su, +18 authors, Yi Gu.
Oncotarget, 2017 May 04; 8(16). PMID: 28460468    Free PMC article.
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
Kamran A Ahmed, Sungjune Kim, +12 authors, Bradford A Perez.
J Neurooncol, 2017 May 04; 133(2). PMID: 28466250
CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8+ TEM and CD8+ TRM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease.
Ruchi Srivastava, Arif A Khan, +5 authors, Lbachir BenMohamed.
J Virol, 2017 May 05; 91(14). PMID: 28468883    Free PMC article.
Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.
Jay M Lee, Mi-Heon Lee, +23 authors, Steven M Dubinett.
Clin Cancer Res, 2017 May 05; 23(16). PMID: 28468947    Free PMC article.
Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue.
Jessica Kristof, Kellen Sakrison, +6 authors, Wenqin Feng.
Biomark Insights, 2017 May 05; 12. PMID: 28469400    Free PMC article.
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
Allison S Betof, Ryan D Nipp, +7 authors, Ryan J Sullivan.
Oncologist, 2017 May 10; 22(8). PMID: 28476944    Free PMC article.
The KEY to the end of chemotherapy in non-small cell lung cancer?
Yiqing Huang, Ross A Soo.
Ann Transl Med, 2017 May 10; 5(7). PMID: 28480202    Free PMC article.
Pembrolizumab-induced pneumonitis.
Vincent Leroy, Carole Templier, +4 authors, Lidwine Wemeau-Stervinou.
ERJ Open Res, 2017 May 10; 3(2). PMID: 28480216    Free PMC article.
Checkpoint inhibitors in hematological malignancies.
Chi Young Ok, Ken H Young.
J Hematol Oncol, 2017 May 10; 10(1). PMID: 28482851    Free PMC article.
Highly Cited. Review.
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
Esra A Akbay, Shohei Koyama, +21 authors, Kwok-Kin Wong.
J Thorac Oncol, 2017 May 10; 12(8). PMID: 28483607    Free PMC article.
Highly Cited.
Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer.
Kentaro Inamura.
Cancers (Basel), 2017 May 10; 9(5). PMID: 28486396    Free PMC article.
Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.
Kentaro Inamura.
Cells, 2017 May 10; 6(2). PMID: 28486418    Free PMC article.
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
Russell Maxwell, Andrew S Luksik, Tomas Garzon-Muvdi, Michael Lim.
Curr Neurol Neurosci Rep, 2017 May 11; 17(6). PMID: 28488122
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
Sean P Arlauckas, Christopher S Garris, +9 authors, Mikael J Pittet.
Sci Transl Med, 2017 May 12; 9(389). PMID: 28490665    Free PMC article.
Highly Cited.
Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.
C Lim, H S Sekhon, +14 authors, N B Leighl.
Curr Oncol, 2017 May 12; 24(2). PMID: 28490924    Free PMC article.
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.
Prabhsimranjot Singh, Sudhamshi Toom, Yiwu Huang.
J Hematol Oncol, 2017 May 13; 10(1). PMID: 28494772    Free PMC article.
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.
Cristina Ilcus, Cristina Bagacean, +5 authors, Mihnea Zdrenghea.
Onco Targets Ther, 2017 May 13; 10. PMID: 28496333    Free PMC article.
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Marc C Chamberlain, Bryan T Kim.
J Neurooncol, 2017 May 14; 133(3). PMID: 28500559
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Hélène Roussel, Eléonore De Guillebon, +18 authors, Eric Tartour.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507793    Free PMC article.
Evaluation of dosing strategy for pembrolizumab for oncology indications.
Tomoko Freshwater, Anna Kondic, +4 authors, Julie A Stone.
J Immunother Cancer, 2017 May 19; 5. PMID: 28515943    Free PMC article.
Highly Cited.
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, +13 authors, Lisa H Butterfield.
J Immunother Cancer, 2017 May 19; 5. PMID: 28515944    Free PMC article.
Highly Cited. Review.
PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.
Arik Bernard Schulze, Lars Henning Schmidt.
J Thorac Dis, 2017 May 20; 9(4). PMID: 28523184    Free PMC article.
Immunogenomics: using genomics to personalize cancer immunotherapy.
Rance C Siniard, Shuko Harada.
Virchows Arch, 2017 May 22; 471(2). PMID: 28528510
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer.
Salma K Jabbour, Abigail T Berman, Charles B Simone.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529894    Free PMC article.
Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma.
Anusha Kalbasi, Ramesh Rengan.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529899    Free PMC article.
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.
Neil K Taunk, Andreas Rimner, +3 authors, Jamie Chaft.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529900    Free PMC article.
Current state of immunotherapy for non-small cell lung cancer.
Jyoti Malhotra, Salma K Jabbour, Joseph Aisner.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529902    Free PMC article.
Highly Cited. Review.
Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer.
Allison M Campbell, Roy H Decker.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529904    Free PMC article.
[Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Guanhua Zhao, Bin Xu, +8 authors, Xiaoqing Liu.
Zhongguo Fei Ai Za Zhi, 2017 May 24; 20(5). PMID: 28532539    Free PMC article.
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Chethan Ramamurthy, James L Godwin, Hossein Borghaei.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534248
Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
Ji-Yeon Kim, Eunjin Lee, +5 authors, Yeon Hee Park.
Oncotarget, 2017 May 26; 8(29). PMID: 28537889    Free PMC article.
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Caroline Prieux-Klotz, Marie Dior, +6 authors, Romain Coriat.
Target Oncol, 2017 May 26; 12(3). PMID: 28540478
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.
Vera Hirsh.
Onco Targets Ther, 2017 May 27; 10. PMID: 28546756    Free PMC article.
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Narek Shaverdian, Aaron E Lisberg, +5 authors, Percy Lee.
Lancet Oncol, 2017 May 30; 18(7). PMID: 28551359    Free PMC article.
Highly Cited.
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
Akimasa Sekine, Hiroaki Satoh.
Med Oncol, 2017 May 31; 34(7). PMID: 28555261
Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.
Xiaomeng Dai, Jun Xue, +8 authors, Tao Zhang.
Transl Oncol, 2017 May 31; 10(4). PMID: 28558264    Free PMC article.
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
Hongshan Li, Jingyu Yu, +15 authors, Yaning Wang.
J Pharmacokinet Pharmacodyn, 2017 Jun 03; 44(5). PMID: 28573468
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity.
Ryu Watanabe, Tsuyoshi Shirai, +9 authors, Cornelia M Weyand.
J Clin Invest, 2017 Jun 13; 127(7). PMID: 28604383    Free PMC article.
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
J Feng, H Yang, +7 authors, Z Wu.
Oncogene, 2017 Jun 13; 36(42). PMID: 28604752
Highly Cited.
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
Edith Borcoman, Christophe Le Tourneau.
Ther Adv Med Oncol, 2017 Jun 14; 9(6). PMID: 28607581    Free PMC article.
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Solange Peters, Scott Gettinger, +25 authors, Enriqueta Felip.
J Clin Oncol, 2017 Jun 14; 35(24). PMID: 28609226    Free PMC article.
Highly Cited.
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab.
Li Li, Awais Masood, +2 authors, Alan B Grosbach.
Case Rep Oncol, 2017 Jun 15; 10(1). PMID: 28611636    Free PMC article.
New insights into the role of EMT in tumor immune escape.
Stéphane Terry, Pierre Savagner, +4 authors, Salem Chouaib.
Mol Oncol, 2017 Jun 15; 11(7). PMID: 28614624    Free PMC article.
Highly Cited. Review.
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
C Brüggemann, M C Kirchberger, +14 authors, L Heinzerling.
J Cancer Res Clin Oncol, 2017 Jun 16; 143(10). PMID: 28616701
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
Masao Omata, Ann-Lii Cheng, +18 authors, Shiv Kumar Sarin.
Hepatol Int, 2017 Jun 18; 11(4). PMID: 28620797    Free PMC article.
Highly Cited. Review.
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Opal L Reddy, Peter I Shintaku, Neda A Moatamed.
Diagn Pathol, 2017 Jun 19; 12(1). PMID: 28623908    Free PMC article.
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
Olivier Bylicki, Nicolas Paleiron, +6 authors, Christos Chouaid.
Target Oncol, 2017 Jun 19; 12(5). PMID: 28624922
Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.
Anusha-Preethi Ganesan, James Clarke, +14 authors, Christian H Ottensmeier.
Nat Immunol, 2017 Jun 20; 18(8). PMID: 28628092    Free PMC article.
Highly Cited.
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.
Qian Zhu, Mu-Yan Cai, +7 authors, Jian-Chuan Xia.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638740    Free PMC article.
Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.
Satomi Yagi, Yasuhiro Koh, +11 authors, Nobuyuki Yamamoto.
PLoS One, 2017 Jun 24; 12(6). PMID: 28640869    Free PMC article.
[Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Haiyang Wang, Xiaoqing Yu, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2017 Jun 24; 20(6). PMID: 28641702    Free PMC article.
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.
Jonathan M Lehman, Mary E Gwin, Pierre P Massion.
Curr Oncol Rep, 2017 Jun 24; 19(7). PMID: 28643173
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, +12 authors, Terrill K McClanahan.
J Clin Invest, 2017 Jun 27; 127(8). PMID: 28650338    Free PMC article.
Highly Cited.
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Yuanzeng Min, Kyle C Roche, +12 authors, Andrew Z Wang.
Nat Nanotechnol, 2017 Jun 27; 12(9). PMID: 28650437    Free PMC article.
Highly Cited.
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Julia Judd, Matthew Zibelman, +10 authors, Daniel M Geynisman.
Oncologist, 2017 Jun 28; 22(10). PMID: 28652280    Free PMC article.
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
Sarah Chuzi, Fabio Tavora, +4 authors, Francis J Giles.
Cancer Manag Res, 2017 Jun 28; 9. PMID: 28652812    Free PMC article.
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi.
Nat Rev Clin Oncol, 2017 Jun 28; 14(11). PMID: 28653677    Free PMC article.
Highly Cited. Review.
Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer.
Xiaojun Zhang, Tian Tian, +2 authors, Xiangqun Fang.
Medicine (Baltimore), 2017 Jun 29; 96(26). PMID: 28658153    Free PMC article.
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Hans Brunnström, Anna Johansson, +6 authors, Patrick Micke.
Mod Pathol, 2017 Jul 01; 30(10). PMID: 28664936
Highly Cited.
Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.
Mizuki Nishino, Suzanne E Dahlberg, +5 authors, Mark M Awad.
Clin Cancer Res, 2017 Jul 07; 23(19). PMID: 28679767    Free PMC article.
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.
Julian P Layer, Marie T Kronmüller, +13 authors, Michael Hölzel.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680756    Free PMC article.
Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions.
Frank E Mott.
Oncol Ther, 2017 Jul 07; 5(1). PMID: 28680956    Free PMC article.
Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.
Enrico Franceschi, Santino Minichillo, Alba A Brandes.
CNS Drugs, 2017 Jul 07; 31(8). PMID: 28681349
[Radiotherapy enhances the effect of PD-1 checkpoint inhibitors].
René Baumann, Jürgen Dunst.
Strahlenther Onkol, 2017 Jul 13; 193(9). PMID: 28698902
Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.
Hyosun Cho, Hyojeung Kang, Hwan Hee Lee, Chang Wook Kim.
Int J Mol Sci, 2017 Jul 14; 18(7). PMID: 28703774    Free PMC article.
Development of an intervention to support patients and clinicians with advanced lung cancer when considering systematic anticancer therapy: protocol for the PACT study.
Despina Anagnostou, Stephanie Sivell, +5 authors, Annmarie Nelson.
BMJ Open, 2017 Jul 15; 7(7). PMID: 28706092    Free PMC article.
Novel immunotherapy clinical trials in malignant pleural mesothelioma.
Zachary E Tano, Navin K Chintala, Xiaoyu Li, Prasad S Adusumilli.
Ann Transl Med, 2017 Jul 15; 5(11). PMID: 28706913    Free PMC article.
Cancer Immunotherapies: Are They as Effective in the Elderly?
Kate Poropatich, Joel Fontanarosa, +2 authors, Bin Zhang.
Drugs Aging, 2017 Jul 15; 34(8). PMID: 28707274
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
Jordan Dozier, Hua Zheng, Prasad S Adusumilli.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713676    Free PMC article.
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Cesare Gridelli, Andrea Ardizzoni, +5 authors, Filippo De Marinis.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713682    Free PMC article.
Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.
Laura E Johnson, Brian M Olson, Douglas G McNeel.
J Immunother Cancer, 2017 Jul 19; 5(1). PMID: 28716080    Free PMC article.
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Hyun Tae Lee, Ju Yeon Lee, +6 authors, Yong-Seok Heo.
Sci Rep, 2017 Jul 19; 7(1). PMID: 28717238    Free PMC article.
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Edwin R Parra, Pamela Villalobos, Barbara Mino, Jaime Rodriguez-Canales.
Appl Immunohistochem Mol Morphol, 2017 Jul 19; 26(2). PMID: 28719380    Free PMC article.
Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
Ahmad Al-Sukaini, Francis J Hornicek, +3 authors, Joseph H Schwab.
Clin Orthop Relat Res, 2017 Jul 21; 475(12). PMID: 28725958    Free PMC article.
Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.
Pamela Samson, A Craig Lockhart.
J Gastrointest Oncol, 2017 Jul 25; 8(3). PMID: 28736629    Free PMC article.
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.
Phu N Tran, Sarmen Sarkissian, Joseph Chao, Samuel J Klempner.
Gastrointest Cancer, 2017 Aug 02; 7. PMID: 28757801    Free PMC article.
Neopterin as a biomarker of immune response in cancer patients.
Bohuslav Melichar, Martina Spisarová, +3 authors, Hana Študentová.
Ann Transl Med, 2017 Aug 02; 5(13). PMID: 28758106    Free PMC article.
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan.
Lung Cancer (Auckl), 2017 Aug 02; 8. PMID: 28761384    Free PMC article.
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab.
Ryoji Kato, Hidetoshi Hayashi, +3 authors, Kazuhiko Nakagawa.
ESMO Open, 2017 Aug 02; 2(1). PMID: 28761729    Free PMC article.
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.
Atsuko Kitano, Makiko Ono, +11 authors, Kenji Tamura.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761741    Free PMC article.
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.
Emily Feld, Leora Horn.
Onco Targets Ther, 2017 Aug 05; 10. PMID: 28769573    Free PMC article.
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
Giulia Viale, Dario Trapani, Giuseppe Curigliano.
Biomed Res Int, 2017 Aug 05; 2017. PMID: 28770222    Free PMC article.
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.
Junyu Long, Jianzhen Lin, +7 authors, Haitao Zhao.
J Hematol Oncol, 2017 Aug 05; 10(1). PMID: 28774337    Free PMC article.
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Fengju Chen, Yiqun Zhang, +7 authors, Chad J Creighton.
Nat Commun, 2017 Aug 05; 8(1). PMID: 28775315    Free PMC article.
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Shona Hendry, Roberto Salgado, +97 authors, Stephen B Fox.
Adv Anat Pathol, 2017 Aug 05; 24(5). PMID: 28777142    Free PMC article.
Highly Cited. Review.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Shona Hendry, Roberto Salgado, +97 authors, Stephen B Fox.
Adv Anat Pathol, 2017 Aug 05; 24(6). PMID: 28777143    Free PMC article.
Highly Cited. Review.
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma.
Ying-Fei Li, Jian-Wu Ding, +6 authors, Long Huang.
Mol Clin Oncol, 2017 Aug 07; 7(3). PMID: 28781814    Free PMC article.
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Russell Maxwell, Christopher M Jackson, Michael Lim.
Curr Treat Options Oncol, 2017 Aug 09; 18(8). PMID: 28785997
Lung cancer as a cardiotoxic state: a review.
David Pérez-Callejo, María Torrente, +2 authors, Mariano Provencio.
Med Oncol, 2017 Aug 11; 34(9). PMID: 28795306
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Marius Ilie, Shirin Khambata-Ford, +4 authors, Paul Hofman.
PLoS One, 2017 Aug 11; 12(8). PMID: 28797130    Free PMC article.
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
François Bertucci, Anthony Gonçalves.
Curr Oncol Rep, 2017 Aug 12; 19(10). PMID: 28799073
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Yong-Chen Lu, Linda L Parker, +14 authors, Steven A Rosenberg.
J Clin Oncol, 2017 Aug 16; 35(29). PMID: 28809608    Free PMC article.
Highly Cited.
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Riccardo Mezzadra, Chong Sun, +16 authors, Ton N M Schumacher.
Nature, 2017 Aug 17; 549(7670). PMID: 28813410    Free PMC article.
Highly Cited.
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Sabrina Rossi, Luca Toschi, +3 authors, Egesta Lopci.
Eur J Nucl Med Mol Imaging, 2017 Aug 18; 44(13). PMID: 28815334
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
Aaron Simpson, Wilfride Petnga, +2 authors, Thomas Bogenrieder.
Target Oncol, 2017 Aug 18; 12(5). PMID: 28815409    Free PMC article.
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
Karim Rihawi, Francesco Gelsomino, +4 authors, Andrea Ardizzoni.
Ther Adv Respir Dis, 2017 Aug 19; 11(9). PMID: 28818019    Free PMC article.
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Howard Y Li, Maria McSharry, +8 authors, Raphael A Nemenoff.
Cancer Immunol Res, 2017 Aug 19; 5(9). PMID: 28819064    Free PMC article.
89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.
Christopher G England, Dawei Jiang, +7 authors, Weibo Cai.
Eur J Nucl Med Mol Imaging, 2017 Aug 20; 45(1). PMID: 28821924    Free PMC article.
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
K R Kelly, C M Espitia, +6 authors, S T Nawrocki.
Leukemia, 2017 Aug 24; 32(1). PMID: 28832023    Free PMC article.
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, +6 authors, Razelle Kurzrock.
Mol Cancer Ther, 2017 Aug 25; 16(11). PMID: 28835386    Free PMC article.
Highly Cited.
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
David E Gerber, Paul Swanson, +9 authors, Maria Q Baggstrom.
Lung Cancer, 2017 Aug 26; 111. PMID: 28838379    Free PMC article.
Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients.
Tullia C Bruno, Peggy J Ebner, +11 authors, Jill E Slansky.
Cancer Immunol Res, 2017 Aug 30; 5(10). PMID: 28848053    Free PMC article.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Rachel M Gibbons Johnson, Haidong Dong.
Front Immunol, 2017 Aug 30; 8. PMID: 28848559    Free PMC article.
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
ESMO Open, 2017 Aug 30; 1(6). PMID: 28848660    Free PMC article.
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Carmelo Tibaldi, Alice Lunghi, Editta Baldini.
World J Clin Oncol, 2017 Aug 30; 8(4). PMID: 28848698    Free PMC article.
Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings.
Ai Uchida, Maho Watanabe, +5 authors, Hitoshi Nakashima.
CEN Case Rep, 2017 Aug 30; 6(2). PMID: 28849361    Free PMC article.
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Minghui Zhang, Guoliang Li, +5 authors, Yan Wang.
Sci Rep, 2017 Sep 02; 7(1). PMID: 28860576    Free PMC article.
Highly Cited.
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Hamzeh Albaba, Charles Lim, Natasha B Leighl.
Pharmacoeconomics, 2017 Sep 02; 35(12). PMID: 28861770
Glioblastoma targeted therapy: updated approaches from recent biological insights.
M Touat, A Idbaih, M Sanson, K L Ligon.
Ann Oncol, 2017 Sep 03; 28(7). PMID: 28863449    Free PMC article.
Highly Cited. Review.
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Valsamo Anagnostou, Mark Yarchoan, +6 authors, Patrick M Forde.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864724    Free PMC article.
The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Janice M Mehnert, Arta M Monjazeb, +3 authors, Lyndsay N Harris.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864725    Free PMC article.
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Christina S Baik, Eric H Rubin, +5 authors, Laura Q M Chow.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864727    Free PMC article.
Immune checkpoint inhibitors in cancer therapy.
Eika S Webb, Peng Liu, +3 authors, Yao-He Wang.
J Biomed Res, 2017 Sep 04; 32(5). PMID: 28866656    Free PMC article.
Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.
G Chen, B Zhang, +5 authors, F Wang.
Oncogene, 2017 Sep 05; 36(50). PMID: 28869605
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Weiqiang Zhou, Shanchun Guo, +2 authors, Guangdi Wang.
Curr Med Chem, 2017 Sep 07; 26(17). PMID: 28875842    Free PMC article.
The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report.
Yoko Matsumoto, Tamaki Miura, Hajime Horiuchi, Kazuhiro Usui.
Case Rep Oncol, 2017 Sep 08; 10(2). PMID: 28878661    Free PMC article.
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, +4 authors, Arun K Iyer.
Front Pharmacol, 2017 Sep 08; 8. PMID: 28878676    Free PMC article.
Highly Cited. Review.
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Xiao-Ming Jiang, Yu-Lian Xu, +4 authors, Jin-Jian Lu.
Acta Pharmacol Sin, 2017 Sep 08; 38(11). PMID: 28880013    Free PMC article.
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Tim Müller, Martin Braun, +9 authors, Peter Brossart.
Oncotarget, 2017 Sep 09; 8(32). PMID: 28881780    Free PMC article.
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.
Andrea Cavazzoni, Silvia La Monica, +15 authors, Elisa Giovannetti.
Oncotarget, 2017 Sep 09; 8(32). PMID: 28881794    Free PMC article.
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Manuel D Keller, Christina Neppl, +4 authors, Sabina Berezowska.
Mod Pathol, 2017 Sep 09; 31(1). PMID: 28884747
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
Marianne Davies, Emily A Duffield.
Immunotargets Ther, 2017 Sep 13; 6. PMID: 28894725    Free PMC article.
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Thomas E Heineman, Adam Widman, Edward C Kuan, Maie St John.
Laryngoscope Investig Otolaryngol, 2017 Sep 13; 2(3). PMID: 28894827    Free PMC article.
MafB silencing in macrophages does not influence the initiation and growth of lung cancer induced by urethane.
Takako Nemoto, Yoko Shibata, +15 authors, Isao Kubota.
EXCLI J, 2017 Sep 14; 16. PMID: 28900373    Free PMC article.
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Yu-Pei Chen, Yu Zhang, +9 authors, Jun Ma.
Theranostics, 2017 Sep 16; 7(14). PMID: 28912897    Free PMC article.
Highly Cited.
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Ana C Gregório, Manuela Lacerda, +3 authors, João Nuno Moreira.
Pathol Oncol Res, 2017 Sep 16; 24(4). PMID: 28913723
Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies.
Qing-Ge Zhu, Shi-Ming Zhang, +2 authors, Hu-Qin Zhang.
Oncotarget, 2017 Sep 17; 8(34). PMID: 28915704    Free PMC article.
The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer.
Zhixin Sheng, Xu Zhu, Yanhua Sun, Yanxia Zhang.
Oncotarget, 2017 Sep 17; 8(34). PMID: 28915714    Free PMC article.
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
Ahrong Kim, So Jeong Lee, +7 authors, Kyung Un Choi.
Sci Rep, 2017 Sep 17; 7(1). PMID: 28916815    Free PMC article.
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Sulsal Haque, Mahender Yellu, Jaskirat Randhawa, Nooshin Hashemi-Sadraei.
Drug Des Devel Ther, 2017 Sep 19; 11. PMID: 28919706    Free PMC article.
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Kentaro Inamura, Yusuke Yokouchi, +5 authors, Yuichi Ishikawa.
Cancer Med, 2017 Sep 20; 6(10). PMID: 28925087    Free PMC article.
Predictors of responses to immune checkpoint blockade in advanced melanoma.
N Jacquelot, M P Roberti, +47 authors, L Zitvogel.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928380    Free PMC article.
Highly Cited.
Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.
Sameera S Kumar, Kristin A Higgins, Ronald C McGarry.
Front Oncol, 2017 Sep 21; 7. PMID: 28929083    Free PMC article.
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Yunjian Pan, Difan Zheng, +11 authors, Haiquan Chen.
J Thorac Dis, 2017 Sep 22; 9(8). PMID: 28932565    Free PMC article.
Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Nicholas M Mark, Julia Kargl, +7 authors, A McGarry Houghton.
Am J Respir Crit Care Med, 2017 Sep 22; 197(3). PMID: 28934595    Free PMC article.
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Sasagu Kurozumi, Takaaki Fujii, +4 authors, Hiroyuki Kuwano.
Med Mol Morphol, 2017 Sep 25; 50(4). PMID: 28936553
PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.
Qiang Su, Zhigang Sun, +2 authors, Bangwei Cao.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938671    Free PMC article.
Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.
Xiaohui Wang, Zhengqiang Bao, +7 authors, Songmin Ying.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938692    Free PMC article.
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
Theresa Scognamiglio, Yao-Tseng Chen.
Head Neck Pathol, 2017 Sep 28; 12(2). PMID: 28948509    Free PMC article.
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Ashley M Hopkins, Andrew Rowland, +5 authors, Michael J Sorich.
Br J Cancer, 2017 Sep 28; 117(7). PMID: 28950287    Free PMC article.
Highly Cited. Review.
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Rathi N Pillai, Madhusmita Behera, +6 authors, Suresh S Ramalingam.
Cancer, 2017 Sep 30; 124(2). PMID: 28960263    Free PMC article.
Highly Cited. Systematic Review.
Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer.
Jen-Yu Hung, Meng-Chi Yen, +6 authors, Po-Lin Kuo.
Oncotarget, 2017 Oct 04; 8(38). PMID: 28969021    Free PMC article.
Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes.
Paweł Krawczyk, Bożena Jarosz, +8 authors, Janusz Milanowski.
Oncotarget, 2017 Oct 04; 8(38). PMID: 28969070    Free PMC article.
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
Yulian Khagi, Aaron M Goodman, +5 authors, Razelle Kurzrock.
Clin Cancer Res, 2017 Oct 04; 23(19). PMID: 28972084    Free PMC article.
Highly Cited.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Romualdo Barroso-Sousa, William T Barry, +4 authors, Sara M Tolaney.
JAMA Oncol, 2017 Oct 04; 4(2). PMID: 28973656    Free PMC article.
Highly Cited. Systematic Review.
Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor.
Kah Poh Loh, Chunkit Fung.
Rare Tumors, 2017 Oct 05; 9(2). PMID: 28975019    Free PMC article.
Radiomics: the bridge between medical imaging and personalized medicine.
Philippe Lambin, Ralph T H Leijenaar, +17 authors, Sean Walsh.
Nat Rev Clin Oncol, 2017 Oct 05; 14(12). PMID: 28975929
Highly Cited. Review.
Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer.
Tao Shen, Zhengming Chen, Zhizhuang Joe Zhao, Jie Wu.
Oncotarget, 2017 Oct 06; 8(37). PMID: 28977839    Free PMC article.
Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy.
Jing Ma, Jianhui Li, +7 authors, Kaichun Wu.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978018    Free PMC article.
Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment.
Christina Demuth, Morten Nørgaard Andersen, +2 authors, Boe Sandahl Sørensen.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978110    Free PMC article.
The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken.
Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585
Highly Cited. Review.
Cholangiocarcinoma - evolving concepts and therapeutic strategies.
Sumera Rizvi, Shahid A Khan, +2 authors, Gregory J Gores.
Nat Rev Clin Oncol, 2017 Oct 11; 15(2). PMID: 28994423    Free PMC article.
Highly Cited. Review.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.
Paolo A Ascierto, Bruno Daniele, +5 authors, Sandro Pignata.
J Transl Med, 2017 Oct 13; 15(1). PMID: 29020960    Free PMC article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis.
Peng-Fei Cui, Jun-Xun Ma, +3 authors, Yi Hu.
Ther Clin Risk Manag, 2017 Oct 14; 13. PMID: 29026313    Free PMC article.
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials.
Manni Wang, Xuelei Ma, Linghong Guo, Fan Xia.
Drug Des Devel Ther, 2017 Oct 17; 11. PMID: 29033546    Free PMC article.
Genomic insights into head and neck cancer.
Tim N Beck, Erica A Golemis.
Cancers Head Neck, 2016 Jan 01; 1. PMID: 29034103    Free PMC article.
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
Jordan A Roberts, Raul S Gonzalez, +2 authors, Chanjuan Shi.
Hum Pathol, 2017 Oct 19; 70. PMID: 29037958    Free PMC article.
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Hye Min Kim, Jinae Lee, Ja Seung Koo.
BMC Cancer, 2017 Oct 19; 17(1). PMID: 29041905    Free PMC article.
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.
Chan-Young Ock, Jun-Eul Hwang, +12 authors, Ju-Seog Lee.
Nat Commun, 2017 Oct 21; 8(1). PMID: 29051489    Free PMC article.
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Matthen Mathew, Rachael A Safyan, Catherine A Shu.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057235    Free PMC article.
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Charles Caldwell, Cory E Johnson, +3 authors, Raghuraman Kannan.
Sci Rep, 2017 Oct 24; 7(1). PMID: 29057919    Free PMC article.
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of 
Chinese Lung Cancer Immunotherapy].
Jingjing Liu, Shuang Zhang, Shuang Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2017 Oct 25; 20(10). PMID: 29061217    Free PMC article.
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.
Valentina Rigo, Laura Emionite, +6 authors, Michela Croce.
Sci Rep, 2017 Oct 27; 7(1). PMID: 29070883    Free PMC article.
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
Rivka R Colen, Takeo Fujii, +16 authors, Aung Naing.
Invest New Drugs, 2017 Oct 28; 36(4). PMID: 29075985    Free PMC article.
Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine.
Junwei Li, Madison A Baird, +7 authors, Xiaohu Gao.
Nat Biomed Eng, 2017 Oct 31; 1. PMID: 29082104    Free PMC article.
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
Xueli Nan, Chao Xie, Xueyan Yu, Jie Liu.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088904    Free PMC article.
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting.
Raja Mudad, Manish B Patel, +2 authors, Lincy S Lal.
Lung Cancer (Auckl), 2017 Nov 02; 8. PMID: 29089791    Free PMC article.
Altered miR-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer.
Abouzar Bagheri, Hamid Reza Khorram Khorshid, +6 authors, Mahmood Tavallaie.
Avicenna J Med Biotechnol, 2017 Nov 02; 9(4). PMID: 29090068    Free PMC article.
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
Peng-Fei Wang, Yang Chen, +5 authors, Chang-Xiang Yan.
Front Pharmacol, 2017 Nov 03; 8. PMID: 29093678    Free PMC article.
Highly Cited.
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Smita S Joshi, Steven B Maron, Daniel V Catenacci.
Future Oncol, 2017 Nov 03; 14(5). PMID: 29094609    Free PMC article.
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
Seung Tae Kim, Samuel J Klempner, +6 authors, Jeeyun Lee.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100397    Free PMC article.
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
Lidia M Yshii, Reinhard Hohlfeld, Roland S Liblau.
Nat Rev Neurol, 2017 Nov 07; 13(12). PMID: 29104289
Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells.
Yuki Sakai, Satoshi Mizuta, +5 authors, Yoshimasa Tanaka.
ChemMedChem, 2017 Nov 08; 12(23). PMID: 29110403    Free PMC article.
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.
Mari Mino-Kenudson.
Transl Lung Cancer Res, 2017 Nov 09; 6(5). PMID: 29114473    Free PMC article.
Saudi lung cancer management guidelines 2017.
AR Jazieh on Behalf of Saudi Lung Cancer Guidelines Association, Saudi Lung Cancer Guidelines Members, Abdul Rahman Jazieh, +26 authors, Marie Datario.
Ann Thorac Med, 2017 Nov 10; 12(4). PMID: 29118855    Free PMC article.
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz.
Mol Diagn Ther, 2017 Nov 10; 22(1). PMID: 29119407    Free PMC article.
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Jessica S Brown, Raghav Sundar, Juanita Lopez.
Br J Cancer, 2017 Nov 11; 118(3). PMID: 29123260    Free PMC article.
Highly Cited. Review.
Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France.
Maud Pignata, Christos Chouaid, +4 authors, Stéphane Roze.
Clinicoecon Outcomes Res, 2017 Nov 11; 9. PMID: 29123418    Free PMC article.
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Daniel Y Wang, Fei Ye, Shilin Zhao, Douglas B Johnson.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123955    Free PMC article.
Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.
Haoran Zha, Xiao Han, +5 authors, Bo Zhu.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123963    Free PMC article.
Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.
Paul Zarogoulidis, Haidong Huang, +11 authors, Wolfgang Hohenforst-Schmidt.
Respir Med Case Rep, 2017 Nov 11; 22. PMID: 29124007    Free PMC article.
Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
Marshall L Spiegel, Jonathan W Goldman, +24 authors, Edward B Garon.
Cancer, 2017 Nov 11; 123(24). PMID: 29125624    Free PMC article.
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
Gen Lin, Xirong Fan, +9 authors, Chao Li.
Oncotarget, 2017 Nov 16; 8(48). PMID: 29137398    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Naziheh Assarzadegan, Elizabeth Montgomery, Robert A Anders.
Virchows Arch, 2017 Nov 17; 472(1). PMID: 29143108
Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Dhanusha Sabanathan, John J Park, +3 authors, Howard Gurney.
Oncologist, 2017 Nov 18; 22(12). PMID: 29146617    Free PMC article.
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Minan Wang, Li-Chin Yao, +14 authors, James G Keck.
FASEB J, 2017 Nov 18; 32(3). PMID: 29146734    Free PMC article.
Highly Cited.
Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.
Charny Park, Junhun Cho, +15 authors, Kyoung-Mee Kim.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147610    Free PMC article.
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
Carole Fournier, François Martin, +3 authors, Lionel Apetoh.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147628    Free PMC article.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Kyu Sang Lee, Kyoungyul Lee, +6 authors, Gheeyoung Choe.
J Neurooncol, 2017 Nov 18; 136(3). PMID: 29147863
The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.
Puyuan Xing, Yixiang Zhu, +3 authors, Junling Li.
Oncotarget, 2017 Nov 21; 8(50). PMID: 29152093    Free PMC article.
2015 Review of Newly Approved Oncologic Therapies.
Patrick Medina, Monique Giordana.
J Adv Pract Oncol, 2016 Apr 01; 7(3). PMID: 29152387    Free PMC article.
Immunotherapy and the Treatment of Non-Small Cell Lung Cancer.
Suzanne Walker.
J Adv Pract Oncol, 2016 Apr 01; 7(3). PMID: 29152394    Free PMC article.
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.
Zachary J Brown, Bernd Heinrich, +2 authors, Tim F Greten.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157287    Free PMC article.
PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.
Lianjing Cao, Xinyue Wang, +5 authors, Richeng Jiang.
J Cancer, 2017 Nov 22; 8(16). PMID: 29158797    Free PMC article.
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
Takeo Fujii, Rivka R Colen, +19 authors, Aung Naing.
Invest New Drugs, 2017 Nov 22; 36(4). PMID: 29159766    Free PMC article.
PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
Yoon Jin Cha, Hyo Sup Shim.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163763    Free PMC article.
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Enrico Munari, Giuseppe Zamboni, +15 authors, Giuseppe Bogina.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163815    Free PMC article.
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.
Fei Zhang, Xiaoqiang Qi, +9 authors, Ying Zheng.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163822    Free PMC article.
Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer.
Hui Yang, Jinpeng Shi, +11 authors, Caicun Zhou.
Cancer Med, 2017 Nov 24; 7(1). PMID: 29168339    Free PMC article.
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Hiro Sato, Atsuko Niimi, +14 authors, Atsushi Shibata.
Nat Commun, 2017 Nov 25; 8(1). PMID: 29170499    Free PMC article.
Highly Cited.
Evolution of early phase clinical trials in oncology.
Nam Q Bui, Shivaani Kummar.
J Mol Med (Berl), 2017 Nov 28; 96(1). PMID: 29177698
Optimizing peptide epitope-based autoantibody detection in cancer patients.
Maize Wang, Shirley H Lomeli, +3 authors, Gang Zeng.
Am J Clin Exp Immunol, 2017 Nov 29; 6(5). PMID: 29181273    Free PMC article.
CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells.
Meagan R Rollins, Rachel M Gibbons Johnson.
J Immunol Res, 2017 Nov 29; 2017. PMID: 29181416    Free PMC article.
Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer.
Shaohua Cui, Xinying Su, +9 authors, Liyan Jiang.
J Cancer, 2017 Dec 01; 8(19). PMID: 29187883    Free PMC article.
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.
Wei Wu, Franziska Haderk, Trever G Bivona.
Cancers (Basel), 2017 Dec 01; 9(12). PMID: 29189709    Free PMC article.
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
Claudia Fumarola, Daniele Cretella, +14 authors, Andrea Ardizzoni.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190880    Free PMC article.
Implications of the tumor immune microenvironment for staging and therapeutics.
Janis M Taube, Jérôme Galon, +8 authors, Ashley Cimino-Mathews.
Mod Pathol, 2017 Dec 02; 31(2). PMID: 29192647    Free PMC article.
Highly Cited. Review.
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Michael J Topper, Michelle Vaz, +15 authors, Stephen B Baylin.
Cell, 2017 Dec 02; 171(6). PMID: 29195073    Free PMC article.
Highly Cited.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.
Franz Villarroel-Espindola, Xiaoqing Yu, +9 authors, Kurt A Schalper.
Clin Cancer Res, 2017 Dec 06; 24(7). PMID: 29203588    Free PMC article.
QuPath: Open source software for digital pathology image analysis.
Peter Bankhead, Maurice B Loughrey, +10 authors, Peter W Hamilton.
Sci Rep, 2017 Dec 06; 7(1). PMID: 29203879    Free PMC article.
Highly Cited.
A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice.
Fei Tang, Peng Zhang, +10 authors, Pan Zheng.
Elife, 2017 Dec 06; 6. PMID: 29206103    Free PMC article.
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.
Anna C Filley, Mario Henriquez, Mahua Dey.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207684    Free PMC article.
Highly Cited. Review.
Multiplex three-dimensional optical mapping of tumor immune microenvironment.
Steve Seung-Young Lee, Vytautas P Bindokas, Stephen J Kron.
Sci Rep, 2017 Dec 07; 7(1). PMID: 29208908    Free PMC article.
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.
Pedro Nazareth Aguiar, Ramon Andrade De Mello, +4 authors, Gilberto de Lima Lopes.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209522    Free PMC article.
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis.
Jan Norum, Margareth Aarag Antonsen, +4 authors, Nina Helbekkmo.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209527    Free PMC article.
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
Abhishek D Garg, Sanket More, +6 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209573    Free PMC article.
Highly Cited. Review.
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
Yingyan Yu.
Front Med, 2017 Dec 07; 12(2). PMID: 29209918
Radiotherapy: the key to immunotherapy ignition?
Elaine Luterstein, Narek Shaverdian, Percy Lee.
Oncotarget, 2017 Dec 08; 8(55). PMID: 29212146    Free PMC article.
Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer.
Liwen Zhang, Bojiang Chen, +6 authors, Jie Tian.
Transl Oncol, 2017 Dec 08; 11(1). PMID: 29216508    Free PMC article.
Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.
Xiuning Le, Deepa Rangachari, Daniel B Costa.
J Thorac Dis, 2017 Dec 10; 9(9). PMID: 29221246    Free PMC article.
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.
Luca Toschi, Sabrina Rossi, Giovanna Finocchiaro, Armando Santoro.
Ecancermedicalscience, 2017 Dec 12; 11. PMID: 29225694    Free PMC article.
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.
Xinxin Zhu, Jinghe Lang.
Oncotarget, 2017 Dec 13; 8(57). PMID: 29228642    Free PMC article.
Highly Cited. Review.
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Chan-Young Ock, Sehui Kim, +12 authors, Dae Seog Heo.
Oncotarget, 2017 Dec 13; 8(58). PMID: 29228662    Free PMC article.
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
Hyojin Kim, Hyun Jung Kwon, +2 authors, Jin-Haeng Chung.
Oncotarget, 2017 Dec 13; 8(58). PMID: 29228707    Free PMC article.
Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
Andres Chang, Danielle Schlafer, Christopher R Flowers, Pamela B Allen.
Expert Opin Investig Drugs, 2017 Dec 13; 27(1). PMID: 29228840    Free PMC article.
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Jonathan Lu, Robert A Ramirez.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230122    Free PMC article.
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Michael Dougan.
Front Immunol, 2017 Dec 13; 8. PMID: 29230210    Free PMC article.
Highly Cited. Review.
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
Emily B Tsai, Kelsey Pomykala, +11 authors, Robert Suh.
Radiology, 2017 Dec 13; 287(1). PMID: 29232184    Free PMC article.
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
Mark Lawler, Deborah Alsina, +19 authors, Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative.
Gut, 2017 Dec 14; 67(1). PMID: 29233930    Free PMC article.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
Young Kwang Chae, Ayush Arya, +9 authors, Francis Giles.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29246028    Free PMC article.
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Matthew A Coelho, Sophie de Carné Trécesson, +11 authors, Julian Downward.
Immunity, 2017 Dec 17; 47(6). PMID: 29246442    Free PMC article.
Highly Cited.
The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.
Duncan Simmons, Eddy Lang.
Cureus, 2017 Dec 19; 9(10). PMID: 29250474    Free PMC article.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Rachel E Sanborn, Helen J Ross, +12 authors, Bernard A Fox.
J Immunother Cancer, 2017 Dec 21; 5(1). PMID: 29258618    Free PMC article.
Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.
Lokesh Agrawal, Kelly B Engel, Sarah R Greytak, Helen M Moore.
Semin Cancer Biol, 2017 Dec 21; 52(Pt 2). PMID: 29258857    Free PMC article.
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.
Yuko Oya, Tatsuya Yoshida, +7 authors, Yasushi Yatabe.
Oncotarget, 2017 Dec 22; 8(61). PMID: 29262550    Free PMC article.
A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.
Hongwei Tian, Gang Shi, +12 authors, Hongxin Deng.
Signal Transduct Target Ther, 2017 Dec 22; 1. PMID: 29263903    Free PMC article.
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Chee Khoon Lee, Johnathan Man, +7 authors, James Chih-Hsin Yang.
JAMA Oncol, 2017 Dec 23; 4(2). PMID: 29270615    Free PMC article.
Highly Cited. Systematic Review.
The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.
Atsushi Osoegawa, Hitomi Hiraishi, +6 authors, Kenji Sugio.
In Vivo, 2017 Dec 25; 32(1). PMID: 29275316    Free PMC article.
Live, Learn, Pass It on: A Patient Advocacy Engagement Project on the Lived Experience of Lung Cancer Survivors.
Sydney M Dy, Ellen M Janssen, Andrea Ferris, John Fp Bridges.
J Patient Exp, 2017 Dec 26; 4(4). PMID: 29276762    Free PMC article.
How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.
Marianne Davies.
J Adv Pract Oncol, 2016 Jul 01; 7(5). PMID: 29282426    Free PMC article.
Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.
Elizabeth S Waxman, Frank V Fossella.
J Adv Pract Oncol, 2016 Jul 01; 7(5). PMID: 29282427    Free PMC article.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
Bert H O'Neil, John M Wallmark, +14 authors, Sae-Won Han.
PLoS One, 2017 Dec 29; 12(12). PMID: 29284010    Free PMC article.
Highly Cited.
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
Makoto Tahara, Kei Muro, +6 authors, Yung-Jue Bang.
Cancer Sci, 2017 Dec 29; 109(3). PMID: 29284202    Free PMC article.
Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells.
Shaohua Cui, Lili Dong, +2 authors, Liyan Jiang.
J Cancer, 2018 Jan 02; 9(1). PMID: 29290777    Free PMC article.
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.
Xiang Yan, Li Wang, +11 authors, Bingliang Fang.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296537    Free PMC article.
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Yang-Bo Hu, Qun Zhang, +6 authors, written on behalf of the AME Academic Lung Cancer Cooperation Group.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299404    Free PMC article.
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study.
Aaron Lisberg, Edward B Garon.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299407    Free PMC article.
Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.
Hao Xie, Alex A Adjei.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299408    Free PMC article.
Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.
Marius Ilie, Paul Hofman.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299411    Free PMC article.
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
Alejandro Navarro, Enriqueta Felip.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299418    Free PMC article.
Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.
Ju Hwan Cho.
Immune Netw, 2018 Jan 06; 17(6). PMID: 29302251    Free PMC article.
PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
Shuai Liu, Zheng Wang, +5 authors, Tao Jiang.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308304    Free PMC article.
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.
Emily Z Keung, Jen-Wei Tsai, +10 authors, Christina L Roland.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308306    Free PMC article.
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.
Marie Kostine, Inge H Briaire-de Bruijn, +9 authors, Judith V M G Bovée.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308311    Free PMC article.
Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials.
Wei Wei, Zhibin Luo.
Medicine (Baltimore), 2018 Jan 10; 96(48). PMID: 29310385    Free PMC article.
Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed.
Hai-Yan Tu, Qi Zhang, Yi-Long Wu.
J Thorac Dis, 2018 Jan 10; 9(12). PMID: 29312666    Free PMC article.
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Sean Khozin, Amy P Abernethy, +11 authors, Richard Pazdur.
Oncologist, 2018 Jan 11; 23(3). PMID: 29317551    Free PMC article.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Laura Mezquita, Edouard Auclin, +19 authors, Benjamin Besse.
JAMA Oncol, 2018 Jan 13; 4(3). PMID: 29327044    Free PMC article.
Highly Cited.
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Chi Young Jung, Scott J Antonia.
Tuberc Respir Dis (Seoul), 2018 Jan 15; 81(1). PMID: 29332322    Free PMC article.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Heng Lin, Shuang Wei, +16 authors, Weiping Zou.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337305    Free PMC article.
Highly Cited.
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Dewan Md Sakib Hossain, Sarah Javaid, +8 authors, Alissa Chackerian.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337311    Free PMC article.
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, +29 authors, Matthew D Hellmann.
J Clin Oncol, 2018 Jan 18; 36(7). PMID: 29337640    Free PMC article.
Highly Cited.
CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.
Gwendolyn J McGinnis, Jacob Raber.
Immunotherapy, 2018 Jan 18; 9(11). PMID: 29338610    Free PMC article.
Clinical significance of YAP1 activation in head and neck squamous cell carcinoma.
Young-Gyu Eun, Dongjin Lee, +5 authors, Ju-Seog Lee.
Oncotarget, 2018 Jan 18; 8(67). PMID: 29340043    Free PMC article.
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.
Hong Zhu, Lin-Lin Chang, +8 authors, Bo Yang.
Theranostics, 2018 Jan 19; 8(3). PMID: 29344298    Free PMC article.
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Charlotte Leduc, Julien Adam, +15 authors, Sophie Postel-Vinay.
ESMO Open, 2018 Jan 19; 3(1). PMID: 29344407    Free PMC article.
Checkpoint Inhibitors, Palliative Care, or Hospice.
Mellar P Davis, Rajiv Panikkar.
Curr Oncol Rep, 2018 Jan 20; 20(1). PMID: 29349518
Hypermutated Tumors and Immune Checkpoint Inhibition.
Kristen K Ciombor, Richard M Goldberg.
Drugs, 2018 Jan 20; 78(2). PMID: 29350327
The differences in the assessments of side effects at an oncology outpatient clinic.
A Bayraktar-Ekincioglu, E Kucuk.
Int J Clin Pharm, 2018 Jan 22; 40(2). PMID: 29353396
Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
Felix Wezel, Stefan Vallo, Florian Roghmann, Young Academic Urologist Urothelial Carcinoma Group of the European Association of Urology.
Transl Androl Urol, 2018 Jan 23; 6(6). PMID: 29354494    Free PMC article.
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia.
J Immunother Cancer, 2018 Jan 24; 6(1). PMID: 29357948    Free PMC article.
Highly Cited. Review.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
Theodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360728    Free PMC article.
Highly Cited. Review.
Colorectal Cancers: An Update on Their Molecular Pathology.
Kentaro Inamura.
Cancers (Basel), 2018 Jan 25; 10(1). PMID: 29361689    Free PMC article.
Highly Cited. Review.
The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff.
Nature, 2018 Jan 25; 553(7689). PMID: 29364287
Highly Cited. Review.
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
J Garde-Noguera, P Martin-Martorell, +16 authors, O Juan-Vidal.
Clin Transl Oncol, 2018 Jan 26; 20(8). PMID: 29368144
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
Amy L Cummings, Edward B Garon.
Cancer Biol Med, 2018 Jan 27; 14(4). PMID: 29372100    Free PMC article.
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Haiying Cheng, Alain Borczuk, +6 authors, Xingxing Zang.
Clin Cancer Res, 2018 Jan 28; 24(8). PMID: 29374053    Free PMC article.
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
Aaron Lisberg, D Andrew Tucker, +23 authors, Edward B Garon.
Cancer Immunol Res, 2018 Feb 01; 6(3). PMID: 29382669    Free PMC article.
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Niki Karachaliou, Maria Gonzalez-Cao, +15 authors, Rafael Rosell.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383037    Free PMC article.
Highly Cited.
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.
John Shen, Jason Chang, +3 authors, Rajan P Kulkarni.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383039    Free PMC article.
Role of immune-checkpoint inhibitors in lung cancer.
Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti.
Ther Adv Respir Dis, 2018 Feb 02; 12. PMID: 29385894    Free PMC article.
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Xin Li, Yasong Cheng, +15 authors, Ken H Young.
J Hematol Oncol, 2018 Feb 02; 11(1). PMID: 29386072    Free PMC article.
Highly Cited.
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer.
Chad Tang, Brian Hobbs, +13 authors, Eugene J Koay.
Sci Rep, 2018 Feb 02; 8(1). PMID: 29386574    Free PMC article.
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Anton Uryvaev, Maria Passhak, +2 authors, Gil Bar-Sela.
Med Oncol, 2018 Feb 02; 35(3). PMID: 29388007
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Christophoros Astaras, Rita de Micheli, +2 authors, Andreas F Hottinger.
Curr Neurol Neurosci Rep, 2018 Feb 03; 18(1). PMID: 29392441
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Lea Kristin Röver, Heidrun Gevensleben, +4 authors, Dimo Dietrich.
EBioMedicine, 2018 Feb 06; 28. PMID: 29396294    Free PMC article.
Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.
Koji Nagaoka, Akihiro Hosoi, +3 authors, Kazuhiro Kakimi.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399391    Free PMC article.
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.
Edmund K Moon, Liang-Chuan S Wang, +4 authors, Steven M Albelda.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399394    Free PMC article.
Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer.
Seher Nazlı Kazaz, İlhan Öztop.
Turk Thorac J, 2018 Feb 07; 18(4). PMID: 29404172    Free PMC article.
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Manjima Dhar, Jessica Wong, +8 authors, Rajan P Kulkarni.
Sci Rep, 2018 Feb 09; 8(1). PMID: 29416054    Free PMC article.
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Izak Faiena, Amy L Cummings, +3 authors, Alexandra Drakaki.
Drug Des Devel Ther, 2018 Feb 09; 12. PMID: 29416316    Free PMC article.
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.
Olivier Belzile, Xianming Huang, +4 authors, Bruce D Freimark.
Immunotargets Ther, 2018 Feb 09; 7. PMID: 29417044    Free PMC article.
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Margarita Udall, Maria Rizzo, +4 authors, Eric Faulkner.
Diagn Pathol, 2018 Feb 11; 13(1). PMID: 29426340    Free PMC article.
Highly Cited. Systematic Review.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
G Redelman-Sidi, O Michielin, +4 authors, O Manuel.
Clin Microbiol Infect, 2018 Feb 11; 24 Suppl 2. PMID: 29427804    Free PMC article.
Targeted drugs for systemic therapy of lung cancer with brain metastases.
Ya-Wen Sun, Jian Xu, Jun Zhou, Wen-Juan Liu.
Oncotarget, 2018 Feb 13; 9(4). PMID: 29435193    Free PMC article.
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
Motonobu Saito, Katsuharu Saito, +6 authors, Akiteru Goto.
Mol Clin Oncol, 2018 Feb 13; 8(2). PMID: 29435295    Free PMC article.
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
Christian Manegold, Alex Adjei, +19 authors, Caicun Zhou.
ESMO Open, 2018 Feb 13; 1(6). PMID: 29435365    Free PMC article.
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Ari Vanderwalde, David Spetzler, +2 authors, John Marshall.
Cancer Med, 2018 Feb 13; 7(3). PMID: 29436178    Free PMC article.
Highly Cited.
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Karolina Woroniecka, Pakawat Chongsathidkiet, +19 authors, Peter E Fecci.
Clin Cancer Res, 2018 Feb 14; 24(17). PMID: 29437767    Free PMC article.
Highly Cited.
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Michael B Atkins, Elizabeth R Plimack, +11 authors, Toni K Choueiri.
Lancet Oncol, 2018 Feb 15; 19(3). PMID: 29439857    Free PMC article.
Highly Cited.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Isidro Machado, Jose Antonio López-Guerrero, +2 authors, Antonio Llombart-Bosch.
Virchows Arch, 2018 Feb 16; 472(5). PMID: 29445891
Temozolomide-associated hypermutation in gliomas.
Serah Choi, Yao Yu, +3 authors, Joseph F Costello.
Neuro Oncol, 2018 Feb 17; 20(10). PMID: 29452419    Free PMC article.
Highly Cited. Review.
Analysis of middle- and long-term efficacy of thoracoscope-assisted segmental resection of the lung on non-small cell lung cancer in the early stage.
Ning Ding, Ning Zhou, +2 authors, Min Zhou.
Oncol Lett, 2018 Feb 20; 15(3). PMID: 29456731    Free PMC article.
Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma.
Jae Kyeom Sim, Sang Mi Chung, +10 authors, Sung Yong Lee.
Korean J Intern Med, 2018 Feb 21; 33(4). PMID: 29458244    Free PMC article.
The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
Ryoko Saito, Yasuhiro Miki, +6 authors, Hironobu Sasano.
Int J Mol Sci, 2018 Feb 22; 19(2). PMID: 29463039    Free PMC article.
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Helmy M Guirgis.
J Immunother Cancer, 2018 Feb 22; 6(1). PMID: 29463302    Free PMC article.
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Marzia Del Re, Eleonora Rofi, +6 authors, Romano Danesi.
Oncotarget, 2018 Feb 22; 9(5). PMID: 29464099    Free PMC article.
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.
Alessandro Prestipino, Alica J Emhardt, +46 authors, Robert Zeiser.
Sci Transl Med, 2018 Feb 23; 10(429). PMID: 29467301    Free PMC article.
Highly Cited.
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
Tadashi Sakane, Takayuki Murase, +11 authors, Hiroshi Inagaki.
Oncotarget, 2018 Feb 23; 9(6). PMID: 29467945    Free PMC article.
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
Karen Kelly, Jeffrey R Infante, +8 authors, James L Gulley.
Cancer, 2018 Feb 23; 124(9). PMID: 29469949    Free PMC article.
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
Motohiro Tamiya, Akihiro Tamiya, +12 authors, Fumio Imamura.
PLoS One, 2018 Feb 23; 13(2). PMID: 29470536    Free PMC article.
Highly Cited.
Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.
Hussein Sultan, Takumi Kumai, +6 authors, Esteban Celis.
Cancer Immunol Res, 2018 Feb 28; 6(5). PMID: 29483127    Free PMC article.
Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer.
Chih-Hsi Scott Kuo, Chien-Ying Liu, +11 authors, Cheng-Ta Yang.
Front Immunol, 2018 Feb 28; 9. PMID: 29483918    Free PMC article.
Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer.
Qi Jiang, Mixue Xie, +3 authors, Sufen Yu.
Oncotarget, 2018 Feb 28; 9(7). PMID: 29484143    Free PMC article.
Systemic immune-inflammation index in germ-cell tumours.
Michal Chovanec, Zuzana Cierna, +11 authors, Jozef Mardiak.
Br J Cancer, 2018 Feb 28; 118(6). PMID: 29485980    Free PMC article.
Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Ryo Koda, Hirofumi Watanabe, +5 authors, Ichiei Narita.
BMC Nephrol, 2018 Mar 01; 19(1). PMID: 29486725    Free PMC article.
Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma.
Young Kwang Chae, Jonathan F Anker, +3 authors, Jeffrey H Chuang.
Oncotarget, 2018 Mar 01; 9(8). PMID: 29487705    Free PMC article.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Antje Tunger, Maximilian Kießler, +4 authors, Marc Schmitz.
Biomedicines, 2018 Mar 02; 6(1). PMID: 29494517    Free PMC article.
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.
Geeta Geeta Sharma, Ines Mota, +3 authors, Roberto Chiarle.
Cancers (Basel), 2018 Mar 03; 10(3). PMID: 29495603    Free PMC article.
Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report.
Ziwei Guo, Chao Meng, +2 authors, Jun Liang.
Thorac Cancer, 2018 Mar 03; 9(5). PMID: 29498219    Free PMC article.
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Emily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, Jennifer A Wargo.
Ann Surg Oncol, 2018 Mar 04; 25(7). PMID: 29500764    Free PMC article.
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.
Ju Hwan Cho, Filiz Oezkan, +3 authors, Kai He.
Curr Pharmacol Rep, 2018 Mar 06; 3(6). PMID: 29503796    Free PMC article.
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.
Mark A Samaan, Polychronis Pavlidis, +2 authors, Peter M Irving.
Nat Rev Gastroenterol Hepatol, 2018 Mar 08; 15(4). PMID: 29512649
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Yanchun Li, Mateusz Opyrchal, +4 authors, Thaer Khoury.
Breast Cancer Res Treat, 2018 Mar 11; 170(2). PMID: 29524062    Free PMC article.
Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Andreas H Scheel, Frédérique Penault-Llorca, +6 authors, Josef Rüschoff.
Diagn Pathol, 2018 Mar 14; 13(1). PMID: 29530054    Free PMC article.
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Christian D Fankhauser, Peter J Schüffler, +8 authors, Peter J Wild.
Oncotarget, 2018 Mar 15; 9(12). PMID: 29535806    Free PMC article.
New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.
Takahiro Nakagomi, Taichiro Goto, +8 authors, Masao Omata.
Oncotarget, 2018 Mar 15; 9(12). PMID: 29535832    Free PMC article.
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Kentaro Inamura.
Cancers (Basel), 2018 Mar 15; 10(3). PMID: 29538329    Free PMC article.
Updates on immunotherapy for colorectal cancer.
Aparna Kalyan, Sheetal Kircher, +2 authors, Al Benson.
J Gastrointest Oncol, 2018 Mar 23; 9(1). PMID: 29564182    Free PMC article.
Highly Cited. Review.
Immunotherapy in colorectal cancer: for the select few or all?
Sukeshi Patel Arora, Devalingam Mahalingam.
J Gastrointest Oncol, 2018 Mar 23; 9(1). PMID: 29564183    Free PMC article.
Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers.
Muhammad Shaalan Beg, Jeffrey Meyer.
J Gastrointest Oncol, 2018 Mar 23; 9(1). PMID: 29564188    Free PMC article.
Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
Isaac S Chan, Shailender Bhatia, Howard L Kaufman, Evan J Lipson.
J Immunother Cancer, 2018 Mar 24; 6(1). PMID: 29566749    Free PMC article.
Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.
Maher Albitar, Sucha Sudarsanam, +5 authors, Sally Agersborg.
Oncotarget, 2018 Mar 24; 9(17). PMID: 29568386    Free PMC article.
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.
Daniel Richard Gomez, Lauren Averett Byers, +15 authors, John Victor Heymach.
Oncotarget, 2018 Mar 28; 9(18). PMID: 29581842    Free PMC article.
CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.
Gregor Zaun, Martin Schuler, Ken Herrmann, Andrea Tannapfel.
Dtsch Arztebl Int, 2018 Mar 29; 115(10). PMID: 29587959    Free PMC article.
Immunotherapy in surgically resectable non-small cell lung cancer.
Dwight Owen, Jamie E Chaft.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593886    Free PMC article.
Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Ticiana A Leal, Suresh S Ramalingam.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593888    Free PMC article.
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Sandrine Niyongere, Andreas Saltos, Jhanelle E Gray.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593889    Free PMC article.
Immune checkpoint inhibitors in small cell lung cancer.
Suchita Pakkala, Taofeek K Owonikoko.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593891    Free PMC article.
Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review.
Rodolfo Chicas-Sett, Ignacio Morales-Orue, Delvys Rodriguez-Abreu, Pedro Lara-Jimenez.
Clin Transl Radiat Oncol, 2018 Mar 30; 9. PMID: 29594244    Free PMC article.
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.
Angela Lamarca, Daisuke Nonaka, +10 authors, Juan W Valle.
Oncotarget, 2018 Mar 31; 9(19). PMID: 29599916    Free PMC article.
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.
Matthew A Gubens, Jody C Chuang, +7 authors, Heather A Wakelee.
J Thorac Dis, 2018 Mar 31; 10(1). PMID: 29600052    Free PMC article.
PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Bin Liu, Yoshiki Arakawa, +10 authors, Susumu Miyamoto.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617441    Free PMC article.
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
Hyun-Sung Lee, Hee-Jin Jang, +11 authors, Bryan M Burt.
JCI Insight, 2018 Apr 06; 3(7). PMID: 29618661    Free PMC article.
Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.
Imerio Capone, Paolo Marchetti, +2 authors, Lucia Gabriele.
Front Immunol, 2018 Apr 06; 9. PMID: 29619026    Free PMC article.
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
Denise L Crossland, Warren L Denning, +9 authors, John V Heymach.
Oncogene, 2018 Apr 07; 37(27). PMID: 29622795
Clinical assessment of immune-related adverse events.
Aaron Sosa, Esther Lopez Cadena, +2 authors, Rafael Rosell.
Ther Adv Med Oncol, 2018 Apr 07; 10. PMID: 29623110    Free PMC article.
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Chang-Long Chen, Qiu-Zhong Pan, +17 authors, Jian-Chuan Xia.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632736    Free PMC article.
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Roberta Zappasodi, Taha Merghoub, Jedd D Wolchok.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634946    Free PMC article.
Highly Cited. Review.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Role of PD-1 during effector CD8 T cell differentiation.
Eunseon Ahn, Koichi Araki, +7 authors, Rafi Ahmed.
Proc Natl Acad Sci U S A, 2018 Apr 15; 115(18). PMID: 29654146    Free PMC article.
Highly Cited.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, +32 authors, Drew M Pardoll.
N Engl J Med, 2018 Apr 17; 378(21). PMID: 29658848    Free PMC article.
Highly Cited.
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Chiara Lazzari, Niki Karachaliou, +7 authors, Vanesa Gregorc.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662546    Free PMC article.
Highly Cited. Review.
PD-L1 expression testing in non-small cell lung cancer.
Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemí Reguart.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662547    Free PMC article.
Highly Cited. Review.
Radiotherapy and checkpoint inhibitors: a winning new combination?
Eric C Ko, Silvia C Formenti.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662550    Free PMC article.
Combination Cancer Immunotherapy in Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2018 Apr 18; 7(1). PMID: 29662830    Free PMC article.
Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?
Sylvia C Kurz, Patrick Y Wen.
Curr Treat Options Neurol, 2018 Apr 19; 20(5). PMID: 29666934
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Ari Kassardjian, Peter I Shintaku, Neda A Moatamed.
PLoS One, 2018 Apr 20; 13(4). PMID: 29672601    Free PMC article.
A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.
Wei You, Mei Liu, +5 authors, Hao Peng.
J Cancer, 2018 Apr 21; 9(7). PMID: 29675101    Free PMC article.
Elimination of established tumors with nanodisc-based combination chemoimmunotherapy.
Rui Kuai, Wenmin Yuan, +5 authors, James J Moon.
Sci Adv, 2018 Apr 21; 4(4). PMID: 29675465    Free PMC article.
Highly Cited.
Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Dai Kamamoto, Kentaro Ohara, +3 authors, Hikaru Sasaki.
J Neurooncol, 2018 Apr 21; 139(2). PMID: 29675794
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
Tong Zhang, Xiaomin Song, +20 authors, Kang Li.
Cancer Immunol Immunother, 2018 Apr 25; 67(7). PMID: 29687231    Free PMC article.
Integrative Pharmacology: Advancing Development of Effective Immunotherapies.
Mohammad Tabrizi, Daping Zhang, Vaishnavi Ganti, Glareh Azadi.
AAPS J, 2018 Apr 29; 20(4). PMID: 29704129
Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
Anna W Chalmers, Shiven B Patel, Wallace Akerley.
J Thorac Dis, 2018 May 01; 10(3). PMID: 29707266    Free PMC article.
Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with SLAPenrich.
Francesco Iorio, Luz Garcia-Alonso, +4 authors, Julio Saez-Rodriguez.
Sci Rep, 2018 May 02; 8(1). PMID: 29713020    Free PMC article.
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
Vanda F Torous, Deepa Rangachari, +3 authors, Paul A VanderLaan.
J Am Soc Cytopathol, 2018 May 02; 7(3). PMID: 29713584    Free PMC article.
Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.
Howard Y Li, Maria McSharry, +10 authors, Raphael A Nemenoff.
Oncoimmunology, 2018 May 04; 7(5). PMID: 29721380    Free PMC article.
Immunotherapies: Exploiting the Immune System for Cancer Treatment.
Jeffrey Koury, Mariana Lucero, +8 authors, Andrew Tran.
J Immunol Res, 2018 May 05; 2018. PMID: 29725606    Free PMC article.
Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma.
Takashi Ueno, Takahiro Tsuchikawa, +8 authors, Satoshi Hirano.
Oncotarget, 2018 May 08; 9(28). PMID: 29732001    Free PMC article.
Temozolomide for immunomodulation in the treatment of glioblastoma.
Aida Karachi, Farhad Dastmalchi, Duane A Mitchell, Maryam Rahman.
Neuro Oncol, 2018 May 08; 20(12). PMID: 29733389    Free PMC article.
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe.
Endocr Connect, 2018 May 10; 7(5). PMID: 29739808    Free PMC article.
Combination Immunotherapy in Non-small Cell Lung Cancer.
Melina E Marmarelis, Charu Aggarwal.
Curr Oncol Rep, 2018 May 10; 20(7). PMID: 29740718
Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report.
Yoshihiro Nozawa, Yuka Oka, Jun Oosugi, Shinichi Takemura.
Medicine (Baltimore), 2018 May 10; 97(19). PMID: 29742733    Free PMC article.
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital.
Ria Winkelmann, Markus Schneider, +5 authors, Dirk Walter.
Int J Mol Sci, 2018 May 12; 19(5). PMID: 29747443    Free PMC article.
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Hossein Maymani, Kenneth Hess, +14 authors, Vivek Subbiah.
Lung Cancer, 2018 May 12; 120. PMID: 29748008    Free PMC article.
Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.
Zheng-Hang Wang, Lin Shen.
Chronic Dis Transl Med, 2018 May 15; 4(1). PMID: 29756118    Free PMC article.
Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.
Tae-Ok Kim, In-Jae Oh, +10 authors, Yoo-Duk Choi.
Thorac Cancer, 2018 May 16; 9(7). PMID: 29761660    Free PMC article.
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
Masayuki Takeda, Kazuko Sakai, +6 authors, Kazuhiko Nakagawa.
Oncotarget, 2018 May 17; 9(30). PMID: 29765525    Free PMC article.
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Young Kwang Chae, Ayush Arya, +4 authors, Francis Giles.
J Immunother Cancer, 2018 May 18; 6(1). PMID: 29769148    Free PMC article.
Highly Cited. Review.
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, +66 authors, John V Heymach.
Cancer Discov, 2018 May 19; 8(7). PMID: 29773717    Free PMC article.
Highly Cited.
Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer.
Jan Trøst Jørgensen, Karsten Bork Nielsen.
Transl Lung Cancer Res, 2018 May 22; 7(Suppl 2). PMID: 29780701    Free PMC article.
Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders.
Max A Kruziki, Vidur Sarma, Benjamin J Hackel.
ACS Comb Sci, 2018 May 26; 20(7). PMID: 29799714    Free PMC article.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
Jeremy M O'Connor, Kristen L Fessele, +10 authors, Cary P Gross.
JAMA Oncol, 2018 May 26; 4(8). PMID: 29800974    Free PMC article.
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
Shu-Yung Lin, Ching-Yao Yang, +13 authors, Chong-Jen Yu.
J Cancer, 2018 May 29; 9(10). PMID: 29805708    Free PMC article.
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Mohammed Salhab, Yazan Migdady, +5 authors, James Liebmann.
J Immunother Cancer, 2018 May 31; 6(1). PMID: 29843803    Free PMC article.
Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.
Takehiro Uemura, Toyoaki Hida.
J Thorac Dis, 2018 Jun 01; 10(Suppl 9). PMID: 29850190    Free PMC article.
CNS cancer immunity cycle and strategies to target this for glioblastoma.
Malaka Ameratunga, Niamh Coleman, +2 authors, Juanita Lopez.
Oncotarget, 2018 Jun 02; 9(32). PMID: 29854316    Free PMC article.
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Hyojin Kim, Hyun Jung Kwon, +3 authors, Jin-Haeng Chung.
PLoS One, 2018 Jun 02; 13(6). PMID: 29856861    Free PMC article.
Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Anna Tsiara, Michalis Liontos, +3 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862233    Free PMC article.
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.
Jun Gong, Thang Q Le, +2 authors, Richard Tuli.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866197    Free PMC article.
Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy.
Frederick S Varn, Laura J Tafe, Christopher I Amos, Chao Cheng.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872556    Free PMC article.
Addressing the challenges of applying precision oncology.
Seung Ho Shin, Ann M Bode, Zigang Dong.
NPJ Precis Oncol, 2018 Jun 07; 1(1). PMID: 29872710    Free PMC article.
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
A Lisberg, A Cummings, +23 authors, Edward B Garon.
J Thorac Oncol, 2018 Jun 07; 13(8). PMID: 29874546    Free PMC article.
Highly Cited.
Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.
Howard J Lee, Jing Zeng, Ramesh Rengan.
Transl Lung Cancer Res, 2018 Jun 08; 7(2). PMID: 29876317    Free PMC article.
Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Yumi Katsume, Tsuyoshi Isawa, +4 authors, Tatsushi Ootomo.
Intern Med, 2018 Jun 08; 57(21). PMID: 29877257    Free PMC article.
The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
Akifumi Tabei, Mitsuharu Watanabe, +8 authors, Keiju Hiromura.
Intern Med, 2018 Jun 08; 57(21). PMID: 29877267    Free PMC article.
Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Yoshiro Nakahara, Tomoya Fukui, +12 authors, Katsuhiko Naoki.
Intern Med, 2018 Jun 08; 57(21). PMID: 29877291    Free PMC article.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Philipp Metzger, Sabrina V Kirchleitner, +5 authors, Peter Duewell.
Sci Rep, 2018 Jun 13; 8(1). PMID: 29892077    Free PMC article.
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.
Dharmesh Gopalakrishnan, Vadim S Koshkin, +2 authors, Petros Grivas.
Ther Clin Risk Manag, 2018 Jun 13; 14. PMID: 29892196    Free PMC article.
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
N Y L Ngoi, V Heong, +9 authors, D S P Tan.
Gynecol Oncol Rep, 2018 Jun 13; 24. PMID: 29892689    Free PMC article.
The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Yasunori Akutsu, Kentaro Murakami, +8 authors, Hisahiro Matsubara.
Esophagus, 2018 Jun 13; 15(2). PMID: 29892935
Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.
So Hee Dho, Soo Yong Kim, +8 authors, Jae Cheong Lim.
Sci Rep, 2018 Jun 14; 8(1). PMID: 29895866    Free PMC article.
PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.
Giulia Bertolini, Luca Bergamaschi, +11 authors, Patrizia Gasparini.
BMC Cancer, 2018 Jun 15; 18(1). PMID: 29898687    Free PMC article.
Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma.
Felipe Gálvez-Cancino, Ernesto López, +11 authors, Alvaro Lladser.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900048    Free PMC article.
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.
Kirtesh R Patel, Anthony Martinez, +12 authors, Karen D Godette.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900051    Free PMC article.
Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
Masaru Watanabe, Hirotsugu Kenmotsu, +11 authors, Toshiaki Takahashi.
Cancer Sci, 2018 Jun 15; 109(8). PMID: 29900633    Free PMC article.
Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.
B Melosky.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910649    Free PMC article.
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A Pabani, C A Butts.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910652    Free PMC article.
Advances in the systemic treatment of triple-negative breast cancer.
J M Lebert, R Lester, +2 authors, J McCarthy.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910657    Free PMC article.
Highly Cited. Review.
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Chia-Ing Jan, Wan-Chen Tsai, +5 authors, Der-Yang Cho.
Front Immunol, 2018 Jun 19; 9. PMID: 29910795    Free PMC article.
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Aubhishek Zaman, Trever G Bivona.
Ann Transl Med, 2018 Jun 19; 6(9). PMID: 29911108    Free PMC article.
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Chao-Qun Liu, Jing Xu, +7 authors, Limin Zheng.
Br J Cancer, 2018 Jun 21; 119(1). PMID: 29921949    Free PMC article.
Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Jiang-Dong Sui, Ying Wang, Yue Wan, Yong-Zhong Wu.
Drug Des Devel Ther, 2018 Jun 21; 12. PMID: 29922039    Free PMC article.
Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells.
Jiasen Xie, Zishan Zhou, Shunchang Jiao, Xiaokun Li.
Oncol Lett, 2018 Jun 22; 16(1). PMID: 29928397    Free PMC article.
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Patrick Danaher, Sarah Warren, +6 authors, Alessandra Cesano.
J Immunother Cancer, 2018 Jun 23; 6(1). PMID: 29929551    Free PMC article.
Highly Cited.
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Yukihiro Toi, Shunichi Sugawara, +14 authors, Yoshihiro Honda.
Oncologist, 2018 Jun 24; 23(11). PMID: 29934411    Free PMC article.
Highly Cited.
PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.
Qiao Wang, Fan Feng, +7 authors, Hongwei Zhang.
J Cancer, 2018 Jun 26; 9(12). PMID: 29937943    Free PMC article.
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Verena Rolfes, Christian Idel, +8 authors, Barbara Wollenberg.
Oncotarget, 2018 Jun 26; 9(44). PMID: 29937998    Free PMC article.
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
Filippo de Marinis, Fortunato Ciardiello, +10 authors, Cesare Gridelli.
ESMO Open, 2018 Jun 27; 3(4). PMID: 29942662    Free PMC article.
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Shota Omori, Hirotsugu Kenmotsu, +14 authors, Toshiaki Takahashi.
Int J Clin Oncol, 2018 Jun 28; 23(6). PMID: 29948239
Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?
Andrea Riccardo Filippi, Jacopo Di Muzio, +2 authors, Umberto Ricardi.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951297    Free PMC article.
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951300    Free PMC article.
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara, Sara Pilotto, +7 authors, Emilio Bria.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951307    Free PMC article.
Key questions about the checkpoint blockade-are microRNAs an answer?
Mihnea Dragomir, Baoqing Chen, Xiao Fu, George A Calin.
Cancer Biol Med, 2018 Jun 29; 15(2). PMID: 29951335    Free PMC article.
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Ranee Mehra, Tanguy Y Seiwert, +17 authors, Robert Haddad.
Br J Cancer, 2018 Jun 30; 119(2). PMID: 29955135    Free PMC article.
Highly Cited.
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.
Mark A Perazella, Anushree C Shirali.
J Am Soc Nephrol, 2018 Jul 01; 29(8). PMID: 29959196    Free PMC article.
Highly Cited. Review.
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Muhammad Umair Mushtaq, Athanasios Papadas, +4 authors, Fotis Asimakopoulos.
J Immunother Cancer, 2018 Jul 05; 6(1). PMID: 29970158    Free PMC article.
A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment.
Timothy J Williamson, Alyssa K Choi, +7 authors, Annette L Stanton.
J Thorac Oncol, 2018 Jul 10; 13(9). PMID: 29981926    Free PMC article.
A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung.
Junna Hou, Lihua Xing, Yufen Yuan.
Clin Exp Med, 2018 Jul 11; 18(4). PMID: 29987681
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.
Iris Scherwitzl, Alicia Hurtado, +3 authors, Daniel Meruelo.
Mol Ther Oncolytics, 2018 Jul 11; 9. PMID: 29988525    Free PMC article.
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Kristina Buder-Bakhaya, Jessica C Hassel.
Front Immunol, 2018 Jul 14; 9. PMID: 30002656    Free PMC article.
Highly Cited. Review.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Julie R Brahmer, Ramaswamy Govindan, +18 authors, Roy S Herbst.
J Immunother Cancer, 2018 Jul 18; 6(1). PMID: 30012210    Free PMC article.
The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies.
Gilbert O Fruhwirth, Manfred Kneilling, +3 authors, Erik H J G Aarntzen.
Mol Imaging Biol, 2018 Jul 22; 20(5). PMID: 30030697    Free PMC article.
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Olivier Bylicki, Nicolas Paleiron, Gaëlle Rousseau-Bussac, Christos Chouaïd.
Onco Targets Ther, 2018 Jul 25; 11. PMID: 30038505    Free PMC article.
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience.
Mª Carmen Areses Manrique, Joaquín Mosquera Martínez, +17 authors, José Luis Fírvida Pérez.
Transl Lung Cancer Res, 2018 Jul 28; 7(3). PMID: 30050778    Free PMC article.
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
S P Kang, K Gergich, +4 authors, E H Rubin.
Ann Oncol, 2018 Jul 28; 28(6). PMID: 30052728    Free PMC article.
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
Aleksandra Popovic, Elizabeth M Jaffee, Neeha Zaidi.
J Clin Invest, 2018 Aug 02; 128(8). PMID: 30067248    Free PMC article.
Highly Cited. Review.
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai.
J Thorac Dis, 2018 Aug 03; 10(6). PMID: 30069355    Free PMC article.
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Edward B Garon, Jill M Siegfried, +21 authors, Richard J Pietras.
Lung Cancer, 2018 Aug 10; 123. PMID: 30089602    Free PMC article.
Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.
Alison K Bauer, Misha Umer, +19 authors, Seyed Javad Moghaddam.
JCI Insight, 2018 Aug 10; 3(15). PMID: 30089720    Free PMC article.
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.
Shin Hye Yoo, Bhumsuk Keam, +6 authors, Dae Seog Heo.
ESMO Open, 2018 Aug 11; 3(5). PMID: 30094065    Free PMC article.
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
Jaafar Bennouna, Fabrice Barlesi, +10 authors, Pierre-Jean Souquet.
ESMO Open, 2018 Aug 11; 3(5). PMID: 30094074    Free PMC article.
Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features.
Rebecca Sternschein, Matthew Moll, Julie Ng, Carolyn D'Ambrosio.
Am J Respir Crit Care Med, 2018 Aug 11; 198(7). PMID: 30095979    Free PMC article.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.
S N Gettinger, J Choi, +19 authors, K A Schalper.
Nat Commun, 2018 Aug 12; 9(1). PMID: 30097571    Free PMC article.
Dendritic cell vaccines for high-grade gliomas.
Matthew E Eagles, Farshad Nassiri, +4 authors, Kenneth D Aldape.
Ther Clin Risk Manag, 2018 Aug 14; 14. PMID: 30100728    Free PMC article.
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yiyi Yan, Anagha Bangalore Kumar, +4 authors, Haidong Dong.
Front Immunol, 2018 Aug 14; 9. PMID: 30100909    Free PMC article.
Highly Cited. Review.
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.
Enrico Munari, Giuseppe Zamboni, +13 authors, Giuseppe Bogina.
Oncotarget, 2018 Aug 14; 9(54). PMID: 30101000    Free PMC article.
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
Beatriz Wills, Julie R Brahmer, Jarushka Naidoo.
Curr Treat Options Oncol, 2018 Aug 14; 19(9). PMID: 30101402    Free PMC article.
Targeting the Microenvironment in High Grade Serous Ovarian Cancer.
Nkechiyere G Nwani, Livia E Sima, Wilberto Nieves-Neira, Daniela Matei.
Cancers (Basel), 2018 Aug 15; 10(8). PMID: 30103384    Free PMC article.
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective.
Wenxiao Jiang, Guiqing Cai, Peter C Hu, Yue Wang.
Acta Pharm Sin B, 2018 Aug 16; 8(4). PMID: 30109178    Free PMC article.
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
D E Meyers, P M Bryan, S Banerji, D G Morris.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111979    Free PMC article.
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Muhammad Khan, Jie Lin, +5 authors, Yawei Yuan.
Medicine (Baltimore), 2018 Aug 17; 97(33). PMID: 30113497    Free PMC article.
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.
Yang Liu, Yinping Dong, +3 authors, Jinming Yu.
J Hematol Oncol, 2018 Aug 18; 11(1). PMID: 30115069    Free PMC article.
Highly Cited. Review.
Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report.
Grazia Lazzari, Angela Terlizzi, +4 authors, Giovanni Silvano.
Onco Targets Ther, 2018 Aug 21; 11. PMID: 30122953    Free PMC article.
Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease.
Julius L Decano, Masanori Aikawa.
Front Cardiovasc Med, 2018 Aug 21; 5. PMID: 30123798    Free PMC article.
PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.
Jonathan W Goldman, Basmah Abdalla, +4 authors, Erik L Lum.
BMC Nephrol, 2018 Aug 22; 19(1). PMID: 30126374    Free PMC article.
Design considerations for early-phase clinical trials of immune-oncology agents.
Nolan A Wages, Cody Chiuzan, Katherine S Panageas.
J Immunother Cancer, 2018 Aug 24; 6(1). PMID: 30134959    Free PMC article.
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.
Young-Jun Park, Da-Sol Kuen, Yeonseok Chung.
Exp Mol Med, 2018 Aug 24; 50(8). PMID: 30135516    Free PMC article.
Highly Cited. Review.
Epigenetic mechanisms of tumor resistance to immunotherapy.
Natalia Arenas-Ramirez, Dilara Sahin, Onur Boyman.
Cell Mol Life Sci, 2018 Aug 25; 75(22). PMID: 30140960
MEK inhibitors for the treatment of NRAS mutant melanoma.
Saro Sarkisian, Diwakar Davar.
Drug Des Devel Ther, 2018 Aug 30; 12. PMID: 30154648    Free PMC article.
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Derya Kabacaoglu, Katrin J Ciecielski, Dietrich A Ruess, Hana Algül.
Front Immunol, 2018 Aug 31; 9. PMID: 30158932    Free PMC article.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Hongshu Sui, Ningxia Ma, +4 authors, Jiali Yang.
J Immunol Res, 2018 Aug 31; 2018. PMID: 30159341    Free PMC article.
Highly Cited. Review.
Strategies for Predicting Response to Checkpoint Inhibitors.
Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub.
Curr Hematol Malig Rep, 2018 Aug 31; 13(5). PMID: 30159703    Free PMC article.
Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Jacob Appelbaum, David Wells, +7 authors, Shailender Bhatia.
J Immunother Cancer, 2018 Sep 02; 6(1). PMID: 30170630    Free PMC article.
[Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC].
Shuang Zhang, Jingjing Liu, +2 authors, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2018 Sep 03; 21(8). PMID: 30172268    Free PMC article.
Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study.
Melin J Khandekar, Rakesh Jain.
Transl Cancer Res, 2018 Sep 04; 7(Suppl 1). PMID: 30175050    Free PMC article.
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Guacimara Ortega Sanchez, Kathleen Jahn, +2 authors, Heinz Läubli.
J Immunother Cancer, 2018 Sep 05; 6(1). PMID: 30176946    Free PMC article.
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Lee-Shing Chang, Romualdo Barroso-Sousa, +3 authors, Le Min.
Endocr Rev, 2018 Sep 06; 40(1). PMID: 30184160    Free PMC article.
PD-L1 in melanoma: facts and myths.
Mario Mandalà, Barbara Merelli, Daniela Massi.
Melanoma Manag, 2016 Sep 01; 3(3). PMID: 30190888    Free PMC article.
Immuno-Oncology: Emerging Targets and Combination Therapies.
Henry T Marshall, Mustafa B A Djamgoz.
Front Oncol, 2018 Sep 08; 8. PMID: 30191140    Free PMC article.
Highly Cited. Review.
Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Shouheng Lin, Guohua Huang, +23 authors, Peng Li.
MAbs, 2018 Sep 12; 10(8). PMID: 30204048    Free PMC article.
Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
Klaus Pietzner, Sara Nasser, +4 authors, Jalid Sehouli.
J Gynecol Oncol, 2018 Sep 13; 29(6). PMID: 30207101    Free PMC article.
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.
Jhanelle E Gray, Alberto Chiappori, +15 authors, Scott J Antonia.
Cancer Immunol Immunother, 2018 Sep 14; 67(12). PMID: 30209589    Free PMC article.
Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Martina Vrankar, Karmen Stanic.
Radiol Oncol, 2018 Sep 14; 52(3). PMID: 30210037    Free PMC article.
New advances in immunotherapy for non-small cell lung cancer.
Haifeng Qin, Fang Wang, +4 authors, Hongjun Gao.
Am J Transl Res, 2018 Sep 14; 10(8). PMID: 30210667    Free PMC article.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia.
Marina Wierz, Bassam Janji, +2 authors, Jerome Paggetti.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221064    Free PMC article.
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
Iris Koopmans, Djoke Hendriks, +5 authors, Wijnand Helfrich.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221065    Free PMC article.
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.
Esra A Akbay, James Kim.
Transl Lung Cancer Res, 2018 Sep 19; 7(4). PMID: 30225211    Free PMC article.
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.
Shiro Kimbara, Yutaka Fujiwara, +7 authors, Yuichiro Ohe.
Cancer Sci, 2018 Sep 20; 109(11). PMID: 30230649    Free PMC article.
Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications.
Kaustav Bera, Vamsidhar Velcheti, Anant Madabhushi.
Am Soc Clin Oncol Educ Book, 2018 Sep 21; 38. PMID: 30231314    Free PMC article.
The role of automated cytometry in the new era of cancer immunotherapy.
Marco Danova, Martina Torchio, +3 authors, Giuliano Mazzini.
Mol Clin Oncol, 2018 Sep 21; 9(4). PMID: 30233791    Free PMC article.
Immunotherapy for Merkel Cell Carcinoma.
Kotaro Nagase, Yutaka Narisawa.
Curr Treat Options Oncol, 2018 Sep 22; 19(11). PMID: 30238195
Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Da Hyun Kang, Chaeuk Chung, +6 authors, Jeong Eun Lee.
Thorac Cancer, 2018 Sep 27; 9(11). PMID: 30253080    Free PMC article.
Response to PD1 inhibition in conventional chondrosarcoma.
Michael J Wagner, Robert W Ricciotti, +3 authors, Lee D Cranmer.
J Immunother Cancer, 2018 Sep 27; 6(1). PMID: 30253794    Free PMC article.
Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
Frederick S Varn, Evelien Schaafsma, Yue Wang, Chao Cheng.
Cancer Res, 2018 Sep 27; 78(22). PMID: 30254145    Free PMC article.
Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study).
Yan Xu, Li Zhang, +17 authors, Mengzhao Wang.
Thorac Cancer, 2018 Sep 29; 9(12). PMID: 30264504    Free PMC article.
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
Motoko Tachihara, Shunichi Negoro, +8 authors, Soichiro Yokota.
BMC Cancer, 2018 Oct 05; 18(1). PMID: 30285770    Free PMC article.
The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor.
Qian-Kun Xie, Ping Chen, +10 authors, Liang-Ping Xia.
J Transl Med, 2018 Oct 06; 16(1). PMID: 30286769    Free PMC article.
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Jinfang Zhang, Fabin Dang, Junming Ren, Wenyi Wei.
Trends Biochem Sci, 2018 Oct 06; 43(12). PMID: 30287140    Free PMC article.
Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor.
Sang-Soo Kim, Joe B Harford, +2 authors, Esther H Chang.
Oncoimmunology, 2018 Oct 06; 7(10). PMID: 30288347    Free PMC article.
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Jan Norum, Carsten Nieder.
ESMO Open, 2018 Oct 12; 3(6). PMID: 30305940    Free PMC article.
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.
Paul Lesueur, Alexandre Escande, +9 authors, Radj Gervais.
Cancer Med, 2018 Oct 13; 7(11). PMID: 30311424    Free PMC article.
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Marius Ilié, Mélanie Ngo-Mai, +6 authors, Paul Hofman.
J Vis Exp, 2018 Oct 16; (139). PMID: 30320751    Free PMC article.
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.
Ewelina Grywalska, Marcin Pasiarski, Stanisław Góźdź, Jacek Roliński.
Onco Targets Ther, 2018 Oct 17; 11. PMID: 30323625    Free PMC article.
Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.
Rutika Mehta, Anand Shah, Khaldoun Almhanna.
Onco Targets Ther, 2018 Oct 17; 11. PMID: 30323626    Free PMC article.
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Bin Shao, Chia-Wei Li, +11 authors, Mien-Chie Hung.
Am J Cancer Res, 2018 Oct 17; 8(9). PMID: 30323975    Free PMC article.
The 8th edition AJCC/UICC TNM staging for p16-positive oropharyngeal carcinoma: is there space for improvement?
Shachi Jenny Sharma, Steffen Wagner, +4 authors, Claus Wittekindt.
Eur Arch Otorhinolaryngol, 2018 Oct 18; 275(12). PMID: 30327906
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Masaki Kanazu, Ryuya Edahiro, +7 authors, Masahide Mori.
Thorac Cancer, 2018 Oct 18; 9(12). PMID: 30328672    Free PMC article.
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Brian J Christmas, Christine I Rafie, +9 authors, Evanthia T Roussos Torres.
Cancer Immunol Res, 2018 Oct 21; 6(12). PMID: 30341213    Free PMC article.
Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing.
Bo-Lun Zhang, Xu Ji, +18 authors, Hu Tian.
Oncol Lett, 2018 Oct 23; 16(5). PMID: 30344748    Free PMC article.
Predictive biomarkers for tumor immune checkpoint blockade.
Mengting Tong, Jing Wang, +4 authors, Hongliang Zhang.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349382    Free PMC article.
Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
Emily Hinchcliff, David Hong, +5 authors, Amir Jazaeri.
Gynecol Oncol, 2018 Oct 28; 151(3). PMID: 30366646    Free PMC article.
[Predictive value of PD-L1 diagnostics].
H-U Schildhaus.
Pathologe, 2018 Oct 28; 39(6). PMID: 30367225
Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation.
Eric C Ko, Kimberly Thomas Benjamin, Silvia C Formenti.
Adv Radiat Oncol, 2018 Oct 30; 3(4). PMID: 30370347    Free PMC article.
βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
Michal Chovanec, Zuzana Cierna, +10 authors, Jozef Mardiak.
BMC Cancer, 2018 Nov 06; 18(1). PMID: 30390643    Free PMC article.
Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.
Mathew Suji Eapen, Philip M Hansbro, +16 authors, Sukhwinder Singh Sohal.
Drugs, 2018 Nov 06; 78(16). PMID: 30392114
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Niki Karachaliou, Manuel Fernandez-Bruno, Rafael Rosell.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393600    Free PMC article.
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy.
Umberto Malapelle, Antonino Iacca